- Published on
Infectious Disease - Cryptoporidiosis
ESSENTIALS DESCRIPTION
An internal protozoan called Cryptosporidium causes self-limited diarrhea in adults and children as well as prolonged or even fatal diarrhea in HIV-infected patients.
The study of epidemiology
The prevalence
In the United States, the condition affects about 300,000 people annually.
The frequency
• The organism is widely distributed throughout the world; seroprevalence rates can reach up to 75% in underdeveloped nations and 25% in industrialized nations; and elevated transmission is observed in temperate regions.
• In the US, there have been reports of significant waterborne epidemics linked to tainted water sources during warmer months (e.g., Milwaukee, WI).
• Dairy farms and other farms with livestock have been mostly responsible for the poisoning of water systems.
Risk factors include: AIDS patients with chronic diarrhea and a CD4 count less than 100 cells/μL; other immunosuppressive conditions; and children under five in impoverished nations. • Those who handle animals
GENERAL PREVENTION Several measures are advised for those infected with HIV, such as the following:
Steer clear of drinking from pools, rivers, or streams.
Avoiding contact with human or animal excrement; avoiding ingesting water while swimming. Particular caution must be used while handling farm animals or soil that may have been tainted by animal waste.
• It is important to check for Cryptosporidium in the stools of pets who have diarrhea.
• Most water purification techniques, including chlorination, are ineffective against the bacterium.
• When traveling to impoverished nations, stay away from drinking tap water.
• The most effective technique for removing oocysts seems to be filtration. Drinking water can be heated for one minute or filtered to 1 μ.
• Although bottled water may be safer than tap water, purity is not guaranteed and the filtering method may differ among brands.
• Drinks with carbonation are safe.
Pathophysiology
• The intracellular protozoan Cryptosporidium can infect cells that are derived from the epithelium.
• Human gastrointestinal and respiratory cells are among the impacted cells.
• One person goes through the whole life cycle.
• Ingestion of oocysts from water tainted with feces typically results in infection.
• Oocysts can endure in the environment for up to 18 months.
• Research has indicated that consuming fewer than 1000 oocysts may result in illness.
• The pathogen spreads directly from one person to another.
• Other ways that infections might spread include through the
as follows:
Pets, daycare facilities, and hospitals
Intercourse
- Pools
ETIOLOGY • C. hominis • C. meleagridis • C. parvum (most prevalent)
History of Diagnosis
• The incubation period lasts seven to ten days.
• In immunocompetent people, watery diarrhea can range in intensity from two days to a month.
• Abdominal cramps may be experienced by patients.
• There could be a low-grade temperature.
• Less likely than other diarrheal causes to induce vomiting.
• Voluminous diarrhea, up to 15 L/d, can occur in a small percentage of people with immunosuppression, such as HIV infection (mostly in those with CD4 count <50 cells />mu;L).
• Loss of weight with prolonged diarrhea.
Up to 40% of patients may experience a recurrence of the disease. Dyspnea is one of the respiratory symptoms.
Physical examination: Nonspecific results
• Malabsorption wastage
Diagnostic Examination and Interpretation Laboratory
• Giemsa-stained oocysts are seen in stool specimens.
• Round oocysts dyed red or pink against a blue-green backdrop are visible with modified acid-fast stains.
• Assays for antigen detection are more sensitive: The gold standard for feces or tissue specimen staining is now immunofluorescent antibody staining. There are also immunochromatographic or ELISA techniques available.
To find the DNA of C. parvum, use the PCR test.
Leukocytosis is uncommon.
• There are no erythrocytes or leukocytes in the feces.
• Absorption of fat is compromised.
• The majority of patients have abnormal D-Xylose testing.
• Tests for liver function usually reveal increased alkaline phosphatase.
• Low vitamin B12 levels are possible.
Imagining
• Bowel wall edema and an ileus pattern may be seen on radiographs. The results are not specific.
• Biliary involvement: The intrahepatic and extrahepatic bile ducts are dilated or irregular.
• Bilateral pulmonary infiltrates indicate respiratory involvement.
Pathological Results
An intracellular, extracytoplasmic parasite is seen protruding from the mucosal surface's brush boundary in a small intestinal sample.
DIFFERENTIAL DIAGNOSIS • Infections with Clostridium difficile • Salmonella, Shigella, and Campylobacter are examples of enteric bacterial infections
• Mycobacterial infection; • Viral gastroenteritis
• Cytomegalovirus colitis; • Giardia, Cyclospora, Isospora, and Microsporidia infections caused by enteric protozoa
MEDICATION FOR TREATMENT
First Phrase
• Anti-parasitic medications have not been shown to be effective in immunocompromised hosts.
• In patients who are not immunocompromised, nitazoxanide effectively treats diarrhea. Adults and children over the age of twelve can consume 500 mg tablets of nitazoxanide. For three days, 500 mg should be given b.i.d. with food. Nitazoxanide is available as a suspension (powder for reconstitution 100 mg/5 mL) for children aged 1–11. For children ages 1–3, take 100 mg b.i.d. (5 mL) with food for three days; for children ages 4–11, take 200 mg b.i.d. (10 mL) with food for three days. AIDS patients have benefited from the compassionate use of nitazoxanide.Adult dosages ranged from 500 to 1500 mg b.i.d., and treatment is given for at least 14 days in this compassionate use context.
• Oral nonabsorbable aminoglycoside paromomycin has been used with varying degrees of success.For adults aged 25 to
35 mg/kg for two to four weeks in divided dosages. There is no effect of paromomycin on extraintestinal cryptosporidiosis. Combine with antimotility drugs.
• Macrolides that have some activity against Cryptosporidium include azithromycin and clarithromycin.
Line Two
• Azithromycin and paromomycin combined • 600 mg of rifaximin t.i.d. p.o. for 14 days
ADDITIONAL MEDICATION
Overall Actions
• Immunocompetent patients are likely to experience a self-limited sickness that lasts anywhere from a few days to six weeks, during which supportive treatment is provided.
• Supportive care is essential for people with HIV.
Other Treatments
Opiates, loperamide, and diphenoxylate/atropine are examples of antimotility drugs.
• It has been demonstrated that octreotide reduces the production of watery stool without completely eliminating the organism.
• Immune reconstitution using extremely active antiretroviral medications works well for diarrhea in AIDS patients. Note: In vitro, protease inhibitors exhibit anti-cryptosporidial properties.
OTHER PROCEDURES AND SURGERY
In-patient considerations for cholecystectomy for acalculous cholecystitis
Requirements for Admission
Patients who are very dehydrated should be admitted to the hospital, especially kids.
Intravenous Fluids
For patients who are extremely dehydrated, parenteral hydration is used. Add more glucose, bicarbonate, potassium, and sodium.
Continuing Care Follow-Up Suggestions
• There is no need for extra monitoring in immunocompetent patients.
• In patients with HIV or other immunocompromised conditions, aggravation and remission are frequent, although organism eradication is less frequent. Those patients require close monitoring.
DIET: Control undernutrition.
• Steer clear of items that contain lactose because secondary lactose sensitivity is prevalent.
• Supplementing with glutamine may enhance fluid absorption.
PROGNOSIS
illness that goes away on its own in immunocompetent people or in AIDS patients whose CD4 count is greater than 150 cells/μL.
DIFFICULTIES
• Prolonged diarrhea is prevalent and potentially fatal in persons with HIV infection.
• Acalculous cholecystitis and sclerosing cholangitis may result from the organism's involvement of the gallbladder and bile ducts.
• Pancreatitis is possible.
• When the respiratory tract is affected, tracheitis and bronchitis may develop.
ESSENTIALS DESCRIPTION
An internal protozoan called Cryptosporidium causes self-limited diarrhea in adults and children as well as prolonged or even fatal diarrhea in HIV-infected patients.
The study of epidemiology
The prevalence
In the United States, the condition affects about 300,000 people annually.
The frequency
• The organism is widely distributed throughout the world; seroprevalence rates can reach up to 75% in underdeveloped nations and 25% in industrialized nations; and elevated transmission is observed in temperate regions.
• In the US, there have been reports of significant waterborne epidemics linked to tainted water sources during warmer months (e.g., Milwaukee, WI).
• Dairy farms and other farms with livestock have been mostly responsible for the poisoning of water systems.
Risk factors include: AIDS patients with chronic diarrhea and a CD4 count less than 100 cells/μL; other immunosuppressive conditions; and children under five in impoverished nations. • Those who handle animals
GENERAL PREVENTION Several measures are advised for those infected with HIV, such as the following:
Steer clear of drinking from pools, rivers, or streams.
Avoiding contact with human or animal excrement; avoiding ingesting water while swimming. Particular caution must be used while handling farm animals or soil that may have been tainted by animal waste.
• It is important to check for Cryptosporidium in the stools of pets who have diarrhea.
• Most water purification techniques, including chlorination, are ineffective against the bacterium.
• When traveling to impoverished nations, stay away from drinking tap water.
• The most effective technique for removing oocysts seems to be filtration. Drinking water can be heated for one minute or filtered to 1 μ.
• Although bottled water may be safer than tap water, purity is not guaranteed and the filtering method may differ among brands.
• Drinks with carbonation are safe.
Pathophysiology
• The intracellular protozoan Cryptosporidium can infect cells that are derived from the epithelium.
• Human gastrointestinal and respiratory cells are among the impacted cells.
• One person goes through the whole life cycle.
• Ingestion of oocysts from water tainted with feces typically results in infection.
• Oocysts can endure in the environment for up to 18 months.
• Research has indicated that consuming fewer than 1000 oocysts may result in illness.
• The pathogen spreads directly from one person to another.
• Other ways that infections might spread include through the
as follows:
Pets, daycare facilities, and hospitals
Intercourse
- Pools
ETIOLOGY • C. hominis • C. meleagridis • C. parvum (most prevalent)
History of Diagnosis
• The incubation period lasts seven to ten days.
• In immunocompetent people, watery diarrhea can range in intensity from two days to a month.
• Abdominal cramps may be experienced by patients.
• There could be a low-grade temperature.
• Less likely than other diarrheal causes to induce vomiting.
• Voluminous diarrhea, up to 15 L/d, can occur in a small percentage of people with immunosuppression, such as HIV infection (mostly in those with CD4 count <50 cells />mu;L).
• Loss of weight with prolonged diarrhea.
Up to 40% of patients may experience a recurrence of the disease. Dyspnea is one of the respiratory symptoms.
Physical examination: Nonspecific results
• Malabsorption wastage
Diagnostic Examination and Interpretation Laboratory
• Giemsa-stained oocysts are seen in stool specimens.
• Round oocysts dyed red or pink against a blue-green backdrop are visible with modified acid-fast stains.
• Assays for antigen detection are more sensitive: The gold standard for feces or tissue specimen staining is now immunofluorescent antibody staining. There are also immunochromatographic or ELISA techniques available.
To find the DNA of C. parvum, use the PCR test.
Leukocytosis is uncommon.
• There are no erythrocytes or leukocytes in the feces.
• Absorption of fat is compromised.
• The majority of patients have abnormal D-Xylose testing.
• Tests for liver function usually reveal increased alkaline phosphatase.
• Low vitamin B12 levels are possible.
Imagining
• Bowel wall edema and an ileus pattern may be seen on radiographs. The results are not specific.
• Biliary involvement: The intrahepatic and extrahepatic bile ducts are dilated or irregular.
• Bilateral pulmonary infiltrates indicate respiratory involvement.
Pathological Results
An intracellular, extracytoplasmic parasite is seen protruding from the mucosal surface's brush boundary in a small intestinal sample.
DIFFERENTIAL DIAGNOSIS • Infections with Clostridium difficile • Salmonella, Shigella, and Campylobacter are examples of enteric bacterial infections
• Mycobacterial infection; • Viral gastroenteritis
• Cytomegalovirus colitis; • Giardia, Cyclospora, Isospora, and Microsporidia infections caused by enteric protozoa
MEDICATION FOR TREATMENT
First Phrase
• Anti-parasitic medications have not been shown to be effective in immunocompromised hosts.
• In patients who are not immunocompromised, nitazoxanide effectively treats diarrhea. Adults and children over the age of twelve can consume 500 mg tablets of nitazoxanide. For three days, 500 mg should be given b.i.d. with food. Nitazoxanide is available as a suspension (powder for reconstitution 100 mg/5 mL) for children aged 1–11. For children ages 1–3, take 100 mg b.i.d. (5 mL) with food for three days; for children ages 4–11, take 200 mg b.i.d. (10 mL) with food for three days. AIDS patients have benefited from the compassionate use of nitazoxanide.Adult dosages ranged from 500 to 1500 mg b.i.d., and treatment is given for at least 14 days in this compassionate use context.
• Oral nonabsorbable aminoglycoside paromomycin has been used with varying degrees of success.For adults aged 25 to
35 mg/kg for two to four weeks in divided dosages. There is no effect of paromomycin on extraintestinal cryptosporidiosis. Combine with antimotility drugs.
• Macrolides that have some activity against Cryptosporidium include azithromycin and clarithromycin.
Line Two
• Azithromycin and paromomycin combined • 600 mg of rifaximin t.i.d. p.o. for 14 days
ADDITIONAL MEDICATION
Overall Actions
• Immunocompetent patients are likely to experience a self-limited sickness that lasts anywhere from a few days to six weeks, during which supportive treatment is provided.
• Supportive care is essential for people with HIV.
Other Treatments
Opiates, loperamide, and diphenoxylate/atropine are examples of antimotility drugs.
• It has been demonstrated that octreotide reduces the production of watery stool without completely eliminating the organism.
• Immune reconstitution using extremely active antiretroviral medications works well for diarrhea in AIDS patients. Note: In vitro, protease inhibitors exhibit anti-cryptosporidial properties.
OTHER PROCEDURES AND SURGERY
In-patient considerations for cholecystectomy for acalculous cholecystitis
Requirements for Admission
Patients who are very dehydrated should be admitted to the hospital, especially kids.
Intravenous Fluids
For patients who are extremely dehydrated, parenteral hydration is used. Add more glucose, bicarbonate, potassium, and sodium.
Continuing Care Follow-Up Suggestions
• There is no need for extra monitoring in immunocompetent patients.
• In patients with HIV or other immunocompromised conditions, aggravation and remission are frequent, although organism eradication is less frequent. Those patients require close monitoring.
DIET: Control undernutrition.
• Steer clear of items that contain lactose because secondary lactose sensitivity is prevalent.
• Supplementing with glutamine may enhance fluid absorption.
PROGNOSIS
illness that goes away on its own in immunocompetent people or in AIDS patients whose CD4 count is greater than 150 cells/μL.
DIFFICULTIES
• Prolonged diarrhea is prevalent and potentially fatal in persons with HIV infection.
• Acalculous cholecystitis and sclerosing cholangitis may result from the organism's involvement of the gallbladder and bile ducts.
• Pancreatitis is possible.
• When the respiratory tract is affected, tracheitis and bronchitis may develop.
- Published on
Infectious Disease – Common Cold
COMMON COLD BASICS DESCRIPTION
Acute viral infection of the upper respiratory tract
The study of epidemiology
The prevalence
• Two to four colds are reported annually by the average adult.
• Children often report six to ten colds annually.
The frequency
RISK FACTORS
An estimated 1 billion colds occur in the US each year.
• Winter, which causes individuals to congregate inside; • Hand contact with an infected person; • Remaining in a confined space with an infected person
• People with immunocompromised conditions; • Children with undeveloped immune systems
• Psychological stress and smoking enhance susceptibility
GENERAL PREVENTION:
• Wash your hands often; • Avoid touching your nose or eyes.
PATHOPHYSIOLOGY:
A contagious viral infectious disease of the upper respiratory system, it is spread by infected people's aerosol, nasal secretions, or saliva.
• Self-restricting
Etiology
• Coronavirus (10–15%) • Rhinovirus (30–50%)
• Influenza (5–15%)
• Less often are respiratory syncytial virus, adenovirus, enterovirus, metapneumovirus, and parainfluenza.
Acute bronchitis, pharyngitis, pharyngolaryngitis, and rhinorrhea
History of Diagnosis
• 1–3 Rhinorrhea
Sneezing, nasal blockage, laryngitis or throat irritation, coughing, chilliness, and occasionally conjunctivitis, headaches, muscle aches, shivering, and anorexia
PHYSICAL EXAMINATION • Symptoms of upper respiratory tract illness • Fever is unusual
Initial laboratory testing for diagnosis and interpretation
Unless a differential diagnosis is required or problems are expected, no laboratory testing is necessary.
Follow-up and Particular Points to Remember
usually not necessary unless problems are suspected or a differential diagnosis is sought.
Imaging First Step
Not necessary unless problems are suspected or a differential diagnosis is sought.
Follow-up and Particular Points to Remember
Not necessary unless problems are suspected or a differential diagnosis is sought.
Diagnostic/Other Procedures: Usually not necessary
Isolating viruses and directly detecting their antigens
Serology-tests for virus neutralization Sputum and/or throat culture
Testing for influenza viruses
- Nasal discharge culture
DIAGNOSIS DIFFERENTIAL:Infectious
Pneumonia, whooping cough, sinusitis, and influenza are all considered noninfectious.
The condition known as allergic rhinitis
MEDICATION FOR TREATMENT
No antiviral medications with proven benefits
ADDITIONAL MEDICATION
Overall Actions
• Acetaminophen, ibuprofen, and aspirin to treat fever and aches and pains (4)
• Decongestants: Nasal: Rebound effect in individuals who use them for longer than three days; oral: Benefits uncertain
Ipratropium bromide nasal spray: Suggested for both children and adults with nasal congestion; Dextromethorphan: A cough remedy for adults; Antihistamines: First-generation antihistamines to alleviate symptoms in adults
Considerations for Children
• Due to the possibility of Reye's syndrome, children and teenagers should not use aspirin.
• Children should not use codeine, dextromethorphan, or antihistamines.
Referral Issues
Extreme symptoms
Other Treatments
Zinc, vitamin C, and echinacea (5) are not advised for active treatment.
Continuing Care Follow-Up Suggestions
If a cough lasts more than three weeks, it may be a sign of pertussis or pneumonia.
Monitoring of Patients
DIET is typically not necessary.
Drinking lots of water is advised.
PATIENT EDUCATION: Stress that the common cold does not require antibiotics.
Reduce contact with cold-stricken individuals; wash your hands frequently, avoid sharing towels, and drink lots of water. Advise against using nasal drops or sprays excessively as they may create rebound congestion.
• To prevent droplets from spreading, cover your mouth and nose with your arm instead of your hands when you cough or sneeze.
PROGNOSIS
In most cases, the illness is mild and self-limiting.
DIFFICULTIES
Pneumonia, otitis media, sinusitis, pharyngitis, acute bronchitis, and exacerbation of asthma, obstructive sleep apnea, and chronic bronchitis
COMMON COLD BASICS DESCRIPTION
Acute viral infection of the upper respiratory tract
The study of epidemiology
The prevalence
• Two to four colds are reported annually by the average adult.
• Children often report six to ten colds annually.
The frequency
RISK FACTORS
An estimated 1 billion colds occur in the US each year.
• Winter, which causes individuals to congregate inside; • Hand contact with an infected person; • Remaining in a confined space with an infected person
• People with immunocompromised conditions; • Children with undeveloped immune systems
• Psychological stress and smoking enhance susceptibility
GENERAL PREVENTION:
• Wash your hands often; • Avoid touching your nose or eyes.
PATHOPHYSIOLOGY:
A contagious viral infectious disease of the upper respiratory system, it is spread by infected people's aerosol, nasal secretions, or saliva.
• Self-restricting
Etiology
• Coronavirus (10–15%) • Rhinovirus (30–50%)
• Influenza (5–15%)
• Less often are respiratory syncytial virus, adenovirus, enterovirus, metapneumovirus, and parainfluenza.
Acute bronchitis, pharyngitis, pharyngolaryngitis, and rhinorrhea
History of Diagnosis
• 1–3 Rhinorrhea
Sneezing, nasal blockage, laryngitis or throat irritation, coughing, chilliness, and occasionally conjunctivitis, headaches, muscle aches, shivering, and anorexia
PHYSICAL EXAMINATION • Symptoms of upper respiratory tract illness • Fever is unusual
Initial laboratory testing for diagnosis and interpretation
Unless a differential diagnosis is required or problems are expected, no laboratory testing is necessary.
Follow-up and Particular Points to Remember
usually not necessary unless problems are suspected or a differential diagnosis is sought.
Imaging First Step
Not necessary unless problems are suspected or a differential diagnosis is sought.
Follow-up and Particular Points to Remember
Not necessary unless problems are suspected or a differential diagnosis is sought.
Diagnostic/Other Procedures: Usually not necessary
Isolating viruses and directly detecting their antigens
Serology-tests for virus neutralization Sputum and/or throat culture
Testing for influenza viruses
- Nasal discharge culture
DIAGNOSIS DIFFERENTIAL:Infectious
Pneumonia, whooping cough, sinusitis, and influenza are all considered noninfectious.
The condition known as allergic rhinitis
MEDICATION FOR TREATMENT
No antiviral medications with proven benefits
ADDITIONAL MEDICATION
Overall Actions
• Acetaminophen, ibuprofen, and aspirin to treat fever and aches and pains (4)
• Decongestants: Nasal: Rebound effect in individuals who use them for longer than three days; oral: Benefits uncertain
Ipratropium bromide nasal spray: Suggested for both children and adults with nasal congestion; Dextromethorphan: A cough remedy for adults; Antihistamines: First-generation antihistamines to alleviate symptoms in adults
Considerations for Children
• Due to the possibility of Reye's syndrome, children and teenagers should not use aspirin.
• Children should not use codeine, dextromethorphan, or antihistamines.
Referral Issues
Extreme symptoms
Other Treatments
Zinc, vitamin C, and echinacea (5) are not advised for active treatment.
Continuing Care Follow-Up Suggestions
If a cough lasts more than three weeks, it may be a sign of pertussis or pneumonia.
Monitoring of Patients
DIET is typically not necessary.
Drinking lots of water is advised.
PATIENT EDUCATION: Stress that the common cold does not require antibiotics.
Reduce contact with cold-stricken individuals; wash your hands frequently, avoid sharing towels, and drink lots of water. Advise against using nasal drops or sprays excessively as they may create rebound congestion.
• To prevent droplets from spreading, cover your mouth and nose with your arm instead of your hands when you cough or sneeze.
PROGNOSIS
In most cases, the illness is mild and self-limiting.
DIFFICULTIES
Pneumonia, otitis media, sinusitis, pharyngitis, acute bronchitis, and exacerbation of asthma, obstructive sleep apnea, and chronic bronchitis
- Published on
nfectious Disease - CERVICITIS
FUNDAMENTAL DESCRIPTION
Sexually transmitted infection characterized by inflammation of the endocervix and/or ectocervix.
Epidemiology
Prevalence • Common among sexually active adolescent females under 20 years of age • Also observed in young adults aged 20 to 24 years
• A prospective cohort study in the United States with 14,322 young adults aged 18 to 26 years:
The overall prevalence of chlamydial infection was 4.2%.
Women (4.7%) exhibited a higher infection rate than men (3.7%). The incidence was greatest among Black women.
– The overall prevalence of gonorrhea was 0.4%.
The prevalence of coinfection with chlamydial and gonococcal infections was 0.03%.
RISK FACTORS • Recent sexual partner during the last 3 months • Multiple sexual partners within the past 6 months • Sexual partner with several other partners • Irregular use of barrier contraception
GENERAL PREVENTION • Implementation of safe sexual practices • Assessment and treatment of sexual partners
• In instances where medical evaluation, counseling, and partner treatment are unfeasible, patient-delivered therapy serves as an alternative.
• Initiate presumptive treatment when the prevalence of Chlamydia trachomatis or Neisseria gonorrhoeae is elevated, or when adherence to follow-up appointments is considered improbable.
Annual chlamydial screening is advised for all sexually active women aged 25 years or younger, as well as for older women with risk factors, such as having a new or many sex partners.
ETIOLOGY
• Chlamydia trachomatis • Neisseria gonorrhoeae • Mycoplasma hominis, Ureaplasma urealyticum
• Mycoplasma genitalium • Herpes simplex virus • In most instances, no organism is identified • Vaginal infections caused by Trichomonas vaginalis or Candida albicans may extend to the ectocervix • Cytomegalovirus is seldom a causative agent
DIAGNOSTIC HISTORY
• Often asymptomatic • Abnormal vaginal discharge or bleeding, especially post-coitus • Dysuria or increased urinary frequency • Dyspareunia
PHYSICAL EXAMINATION • Presence of yellow exudate in the endocervical canal or on an endocervical swab specimen • Cervical friability observed
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory Preliminary laboratory examinations • cultivation of cervical discharge, encompassing cultivation for N. gonorrhoeae utilizing modified Thayer–Martin media.
• Gram staining
Cytological analysis of endocervical mucus specimens:
– The identification of gram-negative, intracellular diplococci in endocervical mucus is strongly indicative of gonococcal infection. It exhibits just 50% sensitivity in mucopurulent cervicitis, but it demonstrates 95% sensitivity in gonococcal urethritis. Microscopic analysis of ectocervical fluid specimens utilizing standard wet-mount saline and potassium hydroxide. Leukorrhea (>10 WBC per high power field in microscopic analysis of vaginal fluid) is linked to chlamydial and gonococcal infections of the cervix.
Nucleic acid amplification testing for Neisseria gonorrhoeae and Chlamydia trachomatis. This can be conducted on an endocervical sample, vaginal swab specimen, or urine.
• In the presence of cervical ulcers or necrotic lesions, conduct testing for genital herpes using PCR, DFA, virus culture, or type-specific serology.
• Women diagnosed with cervicitis should undergo assessment for bacterial vaginosis, trichomoniasis, and pelvic inflammatory disease.
• Caution: Clean the ectocervix with a swab before to collecting the endocervical mucus samples.
Subsequent Actions & Unique
Considerations • The management of sexual partners should be tailored to the diagnosed or suspected infection.
Patients and their sexual partners must refrain from sexual intercourse until therapy is concluded, specifically 7 days following a single-dose regimen or upon completion of a 7-day regimen, to prevent re-infection.
• In HIV-positive women, the management of cervicitis diminishes viral shedding and the likelihood of HIV transmission.
Pediatric Considerations
In pre-adolescent children, sexual abuse should be regarded as a potential source of chlamydial or gonococcal infection.
THERAPEUTIC PHARMACEUTICAL
Presumptive therapy is warranted when there is a significant incidence of C. trachomatis and N. gonorrhoeae in the local community, coupled with a low probability of patient adherence to follow-up appointments. It is advisable to await test findings prior to commencing treatment if the prevalence of C. trachomatis and N. gonorrhoeae is low and adherence to follow-up visits is probable.
Initial Line
• Chlamydia infection:
– Azithromycin 1 g orally, single dosage, or – Doxycycline 100 mg orally twice day for 7 days
• Gonococcal infection: Administer 250 mg of Ceftriaxone intramuscularly as a single dosage.
• Targeted therapy for alternative etiologies of cervicitis is warranted.
Second Line •
Chlamydial infection: – Ofloxacin 300 mg orally twice day for 7 days Levofloxacin 500 mg orally once daily for seven days
Erythromycin base 500 mg orally four times daily for seven days
• Gonococcal infection: – Administer Cefixime 400 mg orally as a single dosage.
Cefpodoxime 400 mg orally, one administration
The bactericidal level of oral cephalosporins is neither as elevated nor as prolonged as that of ceftriaxone.
– Fluoroquinolones are contraindicated due to rising incidence of gonococcal resistance.
- Spectinomycin 2 g intramuscularly, single administration
Spectinomycin exhibits limited effectiveness in gonococcal pharyngitis.
– It is important to note that Spectinomycin is not currently produced in the United States.
– A solitary 2 g oral administration of azithromycin is efficacious for uncomplicated urogenital gonococcal infection. It is inadvisable due to gastrointestinal intolerance and expense. Moreover, prolonged low concentrations of the medicine may facilitate the development of resistance.
Considerations for Pregnancy:
Primary Line
• Chlamydial infection: – Azithromycin 1 g orally, single dosage ,or – Amoxicillin 500 mg orally three times daily for 7 days
• Theoretically, amoxicillin may lead to a chronic chlamydial infection instead of achieving a microbiological cure. The clinical evidence available are inadequate to substantiate this worry.
• Gonococcal infection: Administer 250 mg of Ceftriaxone intramuscularly as a single dosage. Second Line.
• Chlamydial infection: – Erythromycin base 500 mg orally four times daily for 7 days
Erythromycin base 250 mg orally four times daily for 14 days
Erythromycin ethylsuccinate 800 mg orally four times day for seven days.
Erythromycin ethylsuccinate 400 mg orally four times day for 14 days:
Administer a reduced dosage in cases of gastrointestinal intolerance; fluoroquinolones and tetracyclines are contraindicated.
Erythromycin estolate is contraindicated in pregnancy due to its potential hepatotoxic effects.
• Gonococcal infection: Alternative cephalosporin or spectinomycin
CONTINUING TREATMENT POST-CARE SUGGESTIONS
• A test-of-cure for chlamydial infection is advised solely in the following circumstances:
– If therapy adherence is uncertain – If symptoms continue – If re-infection is suspected – During pregnancy • Follow-up testing should not occur immediately after clinical remission. Non-culture testing for C. trachomatis conducted within three weeks post-successful therapy may yield false-positive results because to the persistent excretion of nonviable organisms.
Patients with simple gonorrhea who have received adequate treatment do not require a test of cure. Patients exhibiting chronic symptoms should undergo culture evaluation for N. gonorrhoeae, and any isolated gonococci must be assessed for antibiotic susceptibility.
• In cases of persistent cervicitis, consider the following: – Re-infection (treat partner) – Bacterial vaginosis • Repeat screening should be contemplated within the initial three to four months post-therapy completion is recommended due to the elevated risk of re-infection, particularly among sexually active teens.
Patient Education: Recommend safe sexual practices.
COMPLICATIONS • Pelvic inflammatory illness • Ectopic pregnancy • Infertility • Chorioamnionitis • Premature rupture of membranes • Puerperal infections
FUNDAMENTAL DESCRIPTION
Sexually transmitted infection characterized by inflammation of the endocervix and/or ectocervix.
Epidemiology
Prevalence • Common among sexually active adolescent females under 20 years of age • Also observed in young adults aged 20 to 24 years
• A prospective cohort study in the United States with 14,322 young adults aged 18 to 26 years:
The overall prevalence of chlamydial infection was 4.2%.
Women (4.7%) exhibited a higher infection rate than men (3.7%). The incidence was greatest among Black women.
– The overall prevalence of gonorrhea was 0.4%.
The prevalence of coinfection with chlamydial and gonococcal infections was 0.03%.
RISK FACTORS • Recent sexual partner during the last 3 months • Multiple sexual partners within the past 6 months • Sexual partner with several other partners • Irregular use of barrier contraception
GENERAL PREVENTION • Implementation of safe sexual practices • Assessment and treatment of sexual partners
• In instances where medical evaluation, counseling, and partner treatment are unfeasible, patient-delivered therapy serves as an alternative.
• Initiate presumptive treatment when the prevalence of Chlamydia trachomatis or Neisseria gonorrhoeae is elevated, or when adherence to follow-up appointments is considered improbable.
Annual chlamydial screening is advised for all sexually active women aged 25 years or younger, as well as for older women with risk factors, such as having a new or many sex partners.
ETIOLOGY
• Chlamydia trachomatis • Neisseria gonorrhoeae • Mycoplasma hominis, Ureaplasma urealyticum
• Mycoplasma genitalium • Herpes simplex virus • In most instances, no organism is identified • Vaginal infections caused by Trichomonas vaginalis or Candida albicans may extend to the ectocervix • Cytomegalovirus is seldom a causative agent
DIAGNOSTIC HISTORY
• Often asymptomatic • Abnormal vaginal discharge or bleeding, especially post-coitus • Dysuria or increased urinary frequency • Dyspareunia
PHYSICAL EXAMINATION • Presence of yellow exudate in the endocervical canal or on an endocervical swab specimen • Cervical friability observed
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory Preliminary laboratory examinations • cultivation of cervical discharge, encompassing cultivation for N. gonorrhoeae utilizing modified Thayer–Martin media.
• Gram staining
Cytological analysis of endocervical mucus specimens:
– The identification of gram-negative, intracellular diplococci in endocervical mucus is strongly indicative of gonococcal infection. It exhibits just 50% sensitivity in mucopurulent cervicitis, but it demonstrates 95% sensitivity in gonococcal urethritis. Microscopic analysis of ectocervical fluid specimens utilizing standard wet-mount saline and potassium hydroxide. Leukorrhea (>10 WBC per high power field in microscopic analysis of vaginal fluid) is linked to chlamydial and gonococcal infections of the cervix.
Nucleic acid amplification testing for Neisseria gonorrhoeae and Chlamydia trachomatis. This can be conducted on an endocervical sample, vaginal swab specimen, or urine.
• In the presence of cervical ulcers or necrotic lesions, conduct testing for genital herpes using PCR, DFA, virus culture, or type-specific serology.
• Women diagnosed with cervicitis should undergo assessment for bacterial vaginosis, trichomoniasis, and pelvic inflammatory disease.
• Caution: Clean the ectocervix with a swab before to collecting the endocervical mucus samples.
Subsequent Actions & Unique
Considerations • The management of sexual partners should be tailored to the diagnosed or suspected infection.
Patients and their sexual partners must refrain from sexual intercourse until therapy is concluded, specifically 7 days following a single-dose regimen or upon completion of a 7-day regimen, to prevent re-infection.
• In HIV-positive women, the management of cervicitis diminishes viral shedding and the likelihood of HIV transmission.
Pediatric Considerations
In pre-adolescent children, sexual abuse should be regarded as a potential source of chlamydial or gonococcal infection.
THERAPEUTIC PHARMACEUTICAL
Presumptive therapy is warranted when there is a significant incidence of C. trachomatis and N. gonorrhoeae in the local community, coupled with a low probability of patient adherence to follow-up appointments. It is advisable to await test findings prior to commencing treatment if the prevalence of C. trachomatis and N. gonorrhoeae is low and adherence to follow-up visits is probable.
Initial Line
• Chlamydia infection:
– Azithromycin 1 g orally, single dosage, or – Doxycycline 100 mg orally twice day for 7 days
• Gonococcal infection: Administer 250 mg of Ceftriaxone intramuscularly as a single dosage.
• Targeted therapy for alternative etiologies of cervicitis is warranted.
Second Line •
Chlamydial infection: – Ofloxacin 300 mg orally twice day for 7 days Levofloxacin 500 mg orally once daily for seven days
Erythromycin base 500 mg orally four times daily for seven days
• Gonococcal infection: – Administer Cefixime 400 mg orally as a single dosage.
Cefpodoxime 400 mg orally, one administration
The bactericidal level of oral cephalosporins is neither as elevated nor as prolonged as that of ceftriaxone.
– Fluoroquinolones are contraindicated due to rising incidence of gonococcal resistance.
- Spectinomycin 2 g intramuscularly, single administration
Spectinomycin exhibits limited effectiveness in gonococcal pharyngitis.
– It is important to note that Spectinomycin is not currently produced in the United States.
– A solitary 2 g oral administration of azithromycin is efficacious for uncomplicated urogenital gonococcal infection. It is inadvisable due to gastrointestinal intolerance and expense. Moreover, prolonged low concentrations of the medicine may facilitate the development of resistance.
Considerations for Pregnancy:
Primary Line
• Chlamydial infection: – Azithromycin 1 g orally, single dosage ,or – Amoxicillin 500 mg orally three times daily for 7 days
• Theoretically, amoxicillin may lead to a chronic chlamydial infection instead of achieving a microbiological cure. The clinical evidence available are inadequate to substantiate this worry.
• Gonococcal infection: Administer 250 mg of Ceftriaxone intramuscularly as a single dosage. Second Line.
• Chlamydial infection: – Erythromycin base 500 mg orally four times daily for 7 days
Erythromycin base 250 mg orally four times daily for 14 days
Erythromycin ethylsuccinate 800 mg orally four times day for seven days.
Erythromycin ethylsuccinate 400 mg orally four times day for 14 days:
Administer a reduced dosage in cases of gastrointestinal intolerance; fluoroquinolones and tetracyclines are contraindicated.
Erythromycin estolate is contraindicated in pregnancy due to its potential hepatotoxic effects.
• Gonococcal infection: Alternative cephalosporin or spectinomycin
CONTINUING TREATMENT POST-CARE SUGGESTIONS
• A test-of-cure for chlamydial infection is advised solely in the following circumstances:
– If therapy adherence is uncertain – If symptoms continue – If re-infection is suspected – During pregnancy • Follow-up testing should not occur immediately after clinical remission. Non-culture testing for C. trachomatis conducted within three weeks post-successful therapy may yield false-positive results because to the persistent excretion of nonviable organisms.
Patients with simple gonorrhea who have received adequate treatment do not require a test of cure. Patients exhibiting chronic symptoms should undergo culture evaluation for N. gonorrhoeae, and any isolated gonococci must be assessed for antibiotic susceptibility.
• In cases of persistent cervicitis, consider the following: – Re-infection (treat partner) – Bacterial vaginosis • Repeat screening should be contemplated within the initial three to four months post-therapy completion is recommended due to the elevated risk of re-infection, particularly among sexually active teens.
Patient Education: Recommend safe sexual practices.
COMPLICATIONS • Pelvic inflammatory illness • Ectopic pregnancy • Infertility • Chorioamnionitis • Premature rupture of membranes • Puerperal infections
- Published on
Infectious Disease – Cat Scratch Disease
CAT-SCRATCH DISEASE (AND BARTONELLA INFECTIONS)
Cat-scratch disease is generally a self-limiting acute condition characterized by regional lymphadenopathy, fever, and systemic symptoms, resulting from Bartonella henselae infection. Other manifestations of B. henselae infection encompass fever of unknown origin, hepatosplenic granulomatous disease, neuroretinitis, and encephalopathy.
Other medically significant Bartonella species comprise: – Bartonella quintana, historically responsible for trench fever, linked with persistent bacteremia, endocarditis, and bacillary angiomatosis. – Bartonella bacilliformis, the etiological agent of Oroya fever.
Epidemiology
Occurrence
The prevalence of cat-scratch disease in the United States is roughly 10 cases per 100,000 person-years, with an estimated 24,000 cases identified annually.
Cat-scratch illness is prevalent globally. In temperate areas, it is seasonal, with the majority of cases occurring from August to January.
Cat-scratch illness manifests in immunocompetent individuals across all age groups, with 80% of cases occurring in those under 21 years old.
Most instances of cat-scratch sickness are self-resolving and linked to regional lymphadenopathy.
B. quintana is considered to be worldwide endemic.
B. bacilliformis infection is transmitted through sand fly bites and is exclusively found at altitudes exceeding 1 km in the Andes mountains.
FACTORS OF RISK
Cats serve as the primary hosts and reservoirs of B. henselae.
Most instances of cat-scratch disease can be directly associated with exposure to cats, particularly kittens or felines infested with fleas. Ninety percent of patients had a history of contact with cats.
- A prior history of cat scratch in 60% of cases.
• Incidences of B. quintana infection have been documented among homeless individuals and those from socioeconomically poor backgrounds. These circumstances render persons susceptible to Pediculus humanus (human body louse), a vector for B. quintana infection.
Patients with advanced HIV infection and other immunocompromised individuals are at elevated risk of
progressive chronic infections induced by B. quintana and B. henselae, encompassing bacillary angiomatosis (vascular lesions) and bacillary peliosis (cystic lesions).
COMPREHENSIVE PREVENTION
The risk of cat-scratch disease can be mitigated by minimizing interactions that could result in scratches, bites, or licks from cats or kittens.
The management of cat fleas may diminish the danger of transmission and may be beneficial in households with immunocompromised individuals.
PATHOPHYSIOLOGY • Bartonella species possess the ability for intracellular persistence and induce inflammation in affected organs.
The inflammatory response in cat-scratch disease leads to localized granuloma development.
ETIOLOGY • Bartonella species are meticulous gram-negative rod-shaped aerobic bacteria. • The predominant cause of cat-scratch disease is B. henselae.
• Additional medically significant Bartonella infections encompass
B. quintana and B. bacilliformis. Numerous additional Bartonella species have been linked to isolated instances of human illness.
FREQUENTLY CO-OCCURRING CONDITIONS
B. henselae and B. quintana induce a unique array of illnesses in HIV infection (see to the preceding section). Chronic infections may also arise in recipients of solid-organ transplants and individuals with hematological malignancies.
HISTORY OF DIAGNOSIS
The primary symptom of cat-scratch disease frequently manifests as a tiny erythematous papule or pustule at the scratch site, which endures for several weeks.
• Consequently, lymph nodes associated with the inoculation site become hypertrophied and sensitive.
Patients with cat-scratch disease may not consistently exhibit fever. Low-grade fever and malaise occur in 30% of patients.
Other indications of cat-scratch disease encompass prolonged fever, neuroretinitis (evidenced by diminished visual acuity or alterations in vision), and encephalopathy (characterized by abnormalities in mental status).
B. henselae bacteremia in individuals infected with HIV is linked to a gradual onset of lethargy, malaise, myalgia, weight loss, recurrent fevers of increasing duration and intensity, and occasionally, headaches. Hepatomegaly may be present.
Trench fever is the quintessential manifestation of B. quintana infection, and its natural progression in healthy individuals has been thoroughly documented. Incubation subsequent to inoculation
may extend from 3 to 38 days before to the typically abrupt emergence of chills and fevers. Afebrile infection represents the least prevalent variant. The accompanying symptoms and signs (e.g., headache, vertigo, retro-orbital pain, conjunctival infection) are all vague.
The physical morphology of bacillary angiomatosis is characterized by subcutaneous or dermal nodules and/or single or numerous dome-shaped papules that are skin-colored or red-to-purple, which may exhibit ulceration, serous or bloody exudate, and crusting. Visceral lesions can be notably striking, both in their quantity and the diversity of their macroscopic appearance.
Bacillary peliosis affects organs characterized by multiple blood-filled cystic formations, varying in size from microscopic to several millimeters.
PHYSICAL EXAM • Regional lymphadenopathy is the predominant physical manifestation in cat-scratch disease, occurring in lymph nodes that drain the inoculation site. • In numerous instances, a tiny granuloma or lesion may be identified at the site of inoculation.
Parinaud’s oculoglandular syndrome occurs in roughly 5% of individuals with cat-scratch disease, characterized by conjunctivitis, conjunctival granuloma, and preauricular lymphadenopathy.
Patients with visceral disease may exhibit hepatosplenomegaly.
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory Initial Assessments
In the initial stages of the disease, the total white blood cell count may reveal mild leukocytosis and an elevated count of polymorphonuclear cells, with eosinophilia observed in 10–20% of individuals.
B. henselae and B. quintana can be isolated from blood using lysis-centrifugation blood cultures; however, both species have also been successfully isolated with the BACTEC blood culture method.
Serological assays for B. henselae are being standardized. Numerous commercial testing laboratories do an indirect fluorescence assay. Low positive titers (1:64–1:256) may indicate recent or past infection, whereas titers beyond 1:256 strongly suggest active infection (2).
Subsequent Actions & Unique Considerations
In instances of inconclusive serology, a repeat test after two weeks may aid in confirming a diagnosis.
Imaging
Ultrasound of swollen lymph nodes can assist in assessing other causes of lymphadenopathy, identifying early suppuration of the bubo, and guiding needle aspiration as necessary.
Diagnostic Procedures and Additional Methods
Excisional biopsy or fine needle aspiration is frequently conducted in instances of regional lymphadenopathy.
Pathological Observations
Pathological findings reveal nonspecific granuloma development in the afflicted lymph nodes. A positive Warthin–Starry stain or tissue PCR for Bartonella indicates the possibility of cat-scratch disease, albeit they are not consistently positive.
DIFFERENTIAL DIAGNOSIS • The diagnosis of cat-scratch illness in individuals exhibiting regional lymphadenopathy or a clinical condition characteristic of cat-scratch disease is indicated by the following:
- Interaction with a feline and the existence of a scratch or
main lesion - A confirmed serological assay for Bartonella
– Distinct histopathologic features (the presence of many microabscesses or granulomas in a lymph node biopsy material)
– Exclusion of other recognizable etiologies, particularly mycobacterial infections and suppurative adenitis
INITIAL THERAPY MEDICATION
The literature contains numerous contradicting assertions regarding the role and selection of antibiotics for cat-scratch illness (3).
• While the condition typically resolves spontaneously, antibiotics may expedite recovery and are hence frequently employed in the treatment of cat-scratch disease.
Azithromycin (500 mg orally as a single dose, followed by 250 mg once day for the subsequent four days) is applicable for adults.
The management of cat-scratch neuroretinitis remains contentious; nonetheless, retrospective studies indicate that the combination of doxycycline and rifampin is linked to a more expedited alleviation of symptoms (4).
For bacillary angiomatosis limited to the skin, an oral regimen of erythromycin 500 mg administered four times daily or doxycycline 100 mg taken twice daily for a duration of 8–12 weeks is advised. Lesions typically start to diminish after a week, but generally require a somewhat longer duration to fully resolve and may result in residual hyperpigmentation.
If unresolved by 12 weeks, therapy should be prolonged.
• A minimum of 4 weeks of treatment is required for bacteremia.
Prolonged treatment (2–3 months) is warranted in an HIV-infected patient with chronic or recurrent fever, particularly in the context of endocarditis.
Second Line
Additional oral medications considered useful against cat-scratch disease include rifampin, ciprofloxacin, and trimethoprim-sulfamethoxazole.
OPERATIVE INTERVENTIONS/ADDITIONAL PROCEDURES
• In the event of suppuration, aspiration should be contemplated to alleviate pain and expedite recovery. Needle aspiration is typically favored over incision and drainage. Following the cleansing of the skin with an iodophor skin cleanser, aspiration can be performed by inserting an 18- or 19-gauge needle tangentially through healthy skin near the base of the node. Reaspiration may be required seldom.
In endocarditis, hemodynamic factors may necessitate valve replacement (see to chapters in Section II on endocarditis).
CONTINUING TREATMENT POST-CARE SUGGESTIONS
The lymphadenopathy associated with cat-scratch illness typically recovers spontaneously over several months.
• A single occurrence of cat-scratch sickness seems to provide enduring immunity. Occasionally, a reemergence of sinus tract drainage from the initially affected nodes may transpire. In cases of large adenopathy (>5 cm), chronic adenopathy may endure for 1 to 2 years.
• The resolution of fever in patients with bacteremia often occurs rapidly in non-HIV-infected individuals, however it may extend to several weeks in those infected with HIV. Typically, bacteremia becomes undetectable within a week of initiating medication, despite the potential continuation of fever.
DIET: Standard.
INFORMATION FOR PATIENTS
Patients must be informed about the transmission method and the possible dangers to immunocompromised others in the household who have comparable exposure to cats.
OUTLOOK
Simple cat-scratch illness has a favorable prognosis. Lymphadenopathy related to mild cat-scratch disease in immunocompetent persons heals within weeks to many months. Complications including retinitis, encephalopathy, or severe systemic disease manifest in 5–14% of instances.
COMPLICATIONS
• Encephalopathy typically manifests many weeks following the severe sickness. Seizures and status epilepticus may indicate encephalopathy but are self-limiting, with prompt recovery typically occurring within a few days. The cerebrospinal fluid is typically normal, although pleocytosis may arise. The etiology of the encephalopathy remains ambiguous, while direct infection, a toxin, and an autoimmune mechanism have been suggested as contributing factors.
Inflammatory responses to B. henselae infection in individuals with AIDS, absent of accompanying angiomatosis or peliosis, have been seen affecting the liver and spleen.
lymph nodes, cardiac organ, and bone marrow
CAT-SCRATCH DISEASE (AND BARTONELLA INFECTIONS)
Cat-scratch disease is generally a self-limiting acute condition characterized by regional lymphadenopathy, fever, and systemic symptoms, resulting from Bartonella henselae infection. Other manifestations of B. henselae infection encompass fever of unknown origin, hepatosplenic granulomatous disease, neuroretinitis, and encephalopathy.
Other medically significant Bartonella species comprise: – Bartonella quintana, historically responsible for trench fever, linked with persistent bacteremia, endocarditis, and bacillary angiomatosis. – Bartonella bacilliformis, the etiological agent of Oroya fever.
Epidemiology
Occurrence
The prevalence of cat-scratch disease in the United States is roughly 10 cases per 100,000 person-years, with an estimated 24,000 cases identified annually.
Cat-scratch illness is prevalent globally. In temperate areas, it is seasonal, with the majority of cases occurring from August to January.
Cat-scratch illness manifests in immunocompetent individuals across all age groups, with 80% of cases occurring in those under 21 years old.
Most instances of cat-scratch sickness are self-resolving and linked to regional lymphadenopathy.
B. quintana is considered to be worldwide endemic.
B. bacilliformis infection is transmitted through sand fly bites and is exclusively found at altitudes exceeding 1 km in the Andes mountains.
FACTORS OF RISK
Cats serve as the primary hosts and reservoirs of B. henselae.
Most instances of cat-scratch disease can be directly associated with exposure to cats, particularly kittens or felines infested with fleas. Ninety percent of patients had a history of contact with cats.
- A prior history of cat scratch in 60% of cases.
• Incidences of B. quintana infection have been documented among homeless individuals and those from socioeconomically poor backgrounds. These circumstances render persons susceptible to Pediculus humanus (human body louse), a vector for B. quintana infection.
Patients with advanced HIV infection and other immunocompromised individuals are at elevated risk of
progressive chronic infections induced by B. quintana and B. henselae, encompassing bacillary angiomatosis (vascular lesions) and bacillary peliosis (cystic lesions).
COMPREHENSIVE PREVENTION
The risk of cat-scratch disease can be mitigated by minimizing interactions that could result in scratches, bites, or licks from cats or kittens.
The management of cat fleas may diminish the danger of transmission and may be beneficial in households with immunocompromised individuals.
PATHOPHYSIOLOGY • Bartonella species possess the ability for intracellular persistence and induce inflammation in affected organs.
The inflammatory response in cat-scratch disease leads to localized granuloma development.
ETIOLOGY • Bartonella species are meticulous gram-negative rod-shaped aerobic bacteria. • The predominant cause of cat-scratch disease is B. henselae.
• Additional medically significant Bartonella infections encompass
B. quintana and B. bacilliformis. Numerous additional Bartonella species have been linked to isolated instances of human illness.
FREQUENTLY CO-OCCURRING CONDITIONS
B. henselae and B. quintana induce a unique array of illnesses in HIV infection (see to the preceding section). Chronic infections may also arise in recipients of solid-organ transplants and individuals with hematological malignancies.
HISTORY OF DIAGNOSIS
The primary symptom of cat-scratch disease frequently manifests as a tiny erythematous papule or pustule at the scratch site, which endures for several weeks.
• Consequently, lymph nodes associated with the inoculation site become hypertrophied and sensitive.
Patients with cat-scratch disease may not consistently exhibit fever. Low-grade fever and malaise occur in 30% of patients.
Other indications of cat-scratch disease encompass prolonged fever, neuroretinitis (evidenced by diminished visual acuity or alterations in vision), and encephalopathy (characterized by abnormalities in mental status).
B. henselae bacteremia in individuals infected with HIV is linked to a gradual onset of lethargy, malaise, myalgia, weight loss, recurrent fevers of increasing duration and intensity, and occasionally, headaches. Hepatomegaly may be present.
Trench fever is the quintessential manifestation of B. quintana infection, and its natural progression in healthy individuals has been thoroughly documented. Incubation subsequent to inoculation
may extend from 3 to 38 days before to the typically abrupt emergence of chills and fevers. Afebrile infection represents the least prevalent variant. The accompanying symptoms and signs (e.g., headache, vertigo, retro-orbital pain, conjunctival infection) are all vague.
The physical morphology of bacillary angiomatosis is characterized by subcutaneous or dermal nodules and/or single or numerous dome-shaped papules that are skin-colored or red-to-purple, which may exhibit ulceration, serous or bloody exudate, and crusting. Visceral lesions can be notably striking, both in their quantity and the diversity of their macroscopic appearance.
Bacillary peliosis affects organs characterized by multiple blood-filled cystic formations, varying in size from microscopic to several millimeters.
PHYSICAL EXAM • Regional lymphadenopathy is the predominant physical manifestation in cat-scratch disease, occurring in lymph nodes that drain the inoculation site. • In numerous instances, a tiny granuloma or lesion may be identified at the site of inoculation.
Parinaud’s oculoglandular syndrome occurs in roughly 5% of individuals with cat-scratch disease, characterized by conjunctivitis, conjunctival granuloma, and preauricular lymphadenopathy.
Patients with visceral disease may exhibit hepatosplenomegaly.
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory Initial Assessments
In the initial stages of the disease, the total white blood cell count may reveal mild leukocytosis and an elevated count of polymorphonuclear cells, with eosinophilia observed in 10–20% of individuals.
B. henselae and B. quintana can be isolated from blood using lysis-centrifugation blood cultures; however, both species have also been successfully isolated with the BACTEC blood culture method.
Serological assays for B. henselae are being standardized. Numerous commercial testing laboratories do an indirect fluorescence assay. Low positive titers (1:64–1:256) may indicate recent or past infection, whereas titers beyond 1:256 strongly suggest active infection (2).
Subsequent Actions & Unique Considerations
In instances of inconclusive serology, a repeat test after two weeks may aid in confirming a diagnosis.
Imaging
Ultrasound of swollen lymph nodes can assist in assessing other causes of lymphadenopathy, identifying early suppuration of the bubo, and guiding needle aspiration as necessary.
Diagnostic Procedures and Additional Methods
Excisional biopsy or fine needle aspiration is frequently conducted in instances of regional lymphadenopathy.
Pathological Observations
Pathological findings reveal nonspecific granuloma development in the afflicted lymph nodes. A positive Warthin–Starry stain or tissue PCR for Bartonella indicates the possibility of cat-scratch disease, albeit they are not consistently positive.
DIFFERENTIAL DIAGNOSIS • The diagnosis of cat-scratch illness in individuals exhibiting regional lymphadenopathy or a clinical condition characteristic of cat-scratch disease is indicated by the following:
- Interaction with a feline and the existence of a scratch or
main lesion - A confirmed serological assay for Bartonella
– Distinct histopathologic features (the presence of many microabscesses or granulomas in a lymph node biopsy material)
– Exclusion of other recognizable etiologies, particularly mycobacterial infections and suppurative adenitis
INITIAL THERAPY MEDICATION
The literature contains numerous contradicting assertions regarding the role and selection of antibiotics for cat-scratch illness (3).
• While the condition typically resolves spontaneously, antibiotics may expedite recovery and are hence frequently employed in the treatment of cat-scratch disease.
Azithromycin (500 mg orally as a single dose, followed by 250 mg once day for the subsequent four days) is applicable for adults.
The management of cat-scratch neuroretinitis remains contentious; nonetheless, retrospective studies indicate that the combination of doxycycline and rifampin is linked to a more expedited alleviation of symptoms (4).
For bacillary angiomatosis limited to the skin, an oral regimen of erythromycin 500 mg administered four times daily or doxycycline 100 mg taken twice daily for a duration of 8–12 weeks is advised. Lesions typically start to diminish after a week, but generally require a somewhat longer duration to fully resolve and may result in residual hyperpigmentation.
If unresolved by 12 weeks, therapy should be prolonged.
• A minimum of 4 weeks of treatment is required for bacteremia.
Prolonged treatment (2–3 months) is warranted in an HIV-infected patient with chronic or recurrent fever, particularly in the context of endocarditis.
Second Line
Additional oral medications considered useful against cat-scratch disease include rifampin, ciprofloxacin, and trimethoprim-sulfamethoxazole.
OPERATIVE INTERVENTIONS/ADDITIONAL PROCEDURES
• In the event of suppuration, aspiration should be contemplated to alleviate pain and expedite recovery. Needle aspiration is typically favored over incision and drainage. Following the cleansing of the skin with an iodophor skin cleanser, aspiration can be performed by inserting an 18- or 19-gauge needle tangentially through healthy skin near the base of the node. Reaspiration may be required seldom.
In endocarditis, hemodynamic factors may necessitate valve replacement (see to chapters in Section II on endocarditis).
CONTINUING TREATMENT POST-CARE SUGGESTIONS
The lymphadenopathy associated with cat-scratch illness typically recovers spontaneously over several months.
• A single occurrence of cat-scratch sickness seems to provide enduring immunity. Occasionally, a reemergence of sinus tract drainage from the initially affected nodes may transpire. In cases of large adenopathy (>5 cm), chronic adenopathy may endure for 1 to 2 years.
• The resolution of fever in patients with bacteremia often occurs rapidly in non-HIV-infected individuals, however it may extend to several weeks in those infected with HIV. Typically, bacteremia becomes undetectable within a week of initiating medication, despite the potential continuation of fever.
DIET: Standard.
INFORMATION FOR PATIENTS
Patients must be informed about the transmission method and the possible dangers to immunocompromised others in the household who have comparable exposure to cats.
OUTLOOK
Simple cat-scratch illness has a favorable prognosis. Lymphadenopathy related to mild cat-scratch disease in immunocompetent persons heals within weeks to many months. Complications including retinitis, encephalopathy, or severe systemic disease manifest in 5–14% of instances.
COMPLICATIONS
• Encephalopathy typically manifests many weeks following the severe sickness. Seizures and status epilepticus may indicate encephalopathy but are self-limiting, with prompt recovery typically occurring within a few days. The cerebrospinal fluid is typically normal, although pleocytosis may arise. The etiology of the encephalopathy remains ambiguous, while direct infection, a toxin, and an autoimmune mechanism have been suggested as contributing factors.
Inflammatory responses to B. henselae infection in individuals with AIDS, absent of accompanying angiomatosis or peliosis, have been seen affecting the liver and spleen.
lymph nodes, cardiac organ, and bone marrow
- Published on
Infectious Disease - Candidiasis
CANDIDIASIS
DESCRIPTION • Candida is a yeast that constitutes part of the normal flora on the skin and within the gastrointestinal and genitourinary tracts. • Candida species are an emerging cause of bloodstream infections in immunocompromised individuals. • Candida can induce both superficial and systemic infections.
Epidemiology: Candidal infections can affect individuals of all ages; however, they are more prevalent among the elderly, babies, and pregnant women.
• A recent study revealed that up to 9% of bloodstream infections in US hospitals were associated with candidal infection.
– Numerous varieties of Candida exist, with Candida albicans being the primary organism associated with the majority of illnesses. Non-albicans Candida species are rising in prevalence. In a recent specimen
Among over 1400 Candida specimens from hospitalized patients, the most prevalent species following C. albicans were C. parapsilosis, C. glabrata, and C. tropicalis.
RISK FACTORS • Immune suppression/neutropenia (2) • Preexisting conditions associated with immune suppression, including cancer, AIDS, and significant burns
• Extended antibiotic administration • Indwelling intravenous catheter • Chemotherapeutic treatment • Recipients of solid organ and bone marrow transplants • Total parenteral nutrition • Chronic renal insufficiency and hemodialysis • Gastrointestinal perforation • Diabetes mellitus • Gestation • Glucocorticoid therapy
GENERAL PREVENTION
• Prudent use of antibiotics. • Extraction of central venous catheters when no longer required.
PATHOPHYSIOLOGY
• Candidemia may arise from disruptions in mucosal barriers at any location within the gastrointestinal system. • Candidemia may also result from the colonization of intravascular catheter devices.
ETIOLOGY • The genus Candida has over 150 species, with the clinically significant species being C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. guilliermondii, and C. lusitaniae. • C. albicans is responsible for over 50% of candidemia cases.
FREQUENTLY CO-OCCURRING CONDITIONS
Immunosuppression due to chemotherapy, HIV/AIDS, solid organ or bone marrow transplantation, neutropenia, or severe underlying conditions necessitating extended ICU admissions with intravenous catheters.
DIAGNOSTIC HISTORY
The clinical presentation and assessment of risk factors are contingent upon the affected organ (e.g., genitourinary and intestinal tracts, brain, skin) and the severity of the disease.
• Vulvovaginal candidiasis: Itching, discomfort, painful urination, painful intercourse, and white, curd-like discharge.
• Oropharyngeal candidiasis: Intermittent discomfort, taste impairment, occasionally asymptomatic.
• Candida esophagitis: Nausea, vomiting, retrosternal chest discomfort, odynophagia, dysphagia.
• Invasive candidiasis: History of immunosuppressive therapy, HIV/AIDS, concomitant malignancy. Mental status alterations may occur if sepsis.
PHYSICAL EXAMINATION
• It is contingent upon the affected organ and the severity of the condition.
• Vulvovaginal candidiasis: Erythema of the vulva or vagina accompanied by a white, curd-like discharge. Occasionally, there is a transparent discharge.
• Oral candidiasis (thrush) and Candida esophagitis: Presence of white plaques on the tongue, hard palate, and soft palate. Frequently results in an erythematous base upon removal. Patients may exhibit esophageal candidiasis in the absence of oral involvement.
Candidemia presents with symptoms ranging from fever to indications of severe sepsis, including hypotension, tachycardia, and alterations in mental status.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• Vulvovaginal candidiasis: Often a clinical diagnosis. The pH of vaginal discharge may vary between 4 and 4.5. Yeast will be observed in microscopic examinations of KOH preparations or wet mounts (3,4).
• Oral candidiasis (thrush): Frequently diagnosed clinically as well. Confirmation can be achieved by examining scrapings on KOH preparations using light microscopy.
Esophageal candidiasis may necessitate endoscopy and biopsy for diagnosis.
Candidemia: Gram staining or proliferation in blood cultures. Candida must not be regarded as a blood contamination.
Susceptibility testing for fluconazole should be conducted in cases of severe infection or in affected people.
ineffective against first-line treatments.
Imaging: Preliminary Strategy
• Neurological assessment: CT scan and MRI of the brain.
• Endocarditis: Transesophageal echocardiography • Esophagitis: Upper endoscopy with biopsy
• Spleen and liver: MRI surpasses CT
Pneumonia: Chest X-ray, Computed Tomography
• Peritonitis: Fluid aspiration guided by CT or ultrasound
Subsequent Actions & Specific Considerations
• For candidemia: Provide general ICU care for stabilization, as death rates may exceed 30–40%.
5–10% of candidemia cases are associated with endophthalmitis complications. Ophthalmology must be consulted in every instance of candidemia.
Diagnostic Procedures/Additional Candida esophagitis: While endoscopy and biopsy represent the definitive method for identifying Candida esophagitis, numerous individuals receive empirical treatment when they exhibit significant symptoms alongside risk factors and oral manifestations.
Candidiasis. It is important to note that oral candidiasis is not a prerequisite for esophageal candidal infections.
Pathological Observations
Yeast exhibiting and lacking pseudohyphae
DIFFERENTIAL DIAGNOSIS
• Oral hairy leukoplakia • Contact dermatitis • Atrophic vaginitis • Bacterial sepsis • Endocarditis • Fever of unknown origin • Cytomegalovirus (CMV) esophagitis
INITIAL THERAPEUTIC AGENT
• Vulvovaginal candidiasis: Various topical treatments are accessible, such as butoconazole cream 5 g/day for 3 days. Oral alternatives are also accessible, including fluconazole 150 mg administered orally as a single dose. Prolonged treatment duration is necessary in severe cases or immunocompromised individuals. Administration of butoconazole cream for 5 to 7 days, or oral fluconazole for up to 7 days, may be required (5–7).
• Oral candidiasis (thrush): Nystatin oral solution (suspension), clotrimazole oral troche, or fluconazole 100–200 mg/day. The therapeutic duration typically spans 5 days following the resolution of symptoms.
Candida esophagitis: Administer Fluconazole 400 mg as a first dose, followed by 200–400 mg daily for a duration of 7–14 days. This can be administered orally, but may be delivered intravenously in certain patients with pronounced dysphagia or odynophagia.
• Candidemia: The selection of empirical therapy is contingent upon the
Candida should undergo culture and sensitivity testing for triazoles (e.g., fluconazole) (8,9). In stable, non-neutropenic patients devoid of antifungal exposure, fluconazole (800 mg intravenously once, followed by 400 mg intravenously daily) is a judicious option. All other patients, including those who are unstable, neutropenic, have prior antifungal exposure, or have experienced recent or extended hospitalizations, should receive empirical treatment with either an echinocandin (caspofungin, micafungin, or anidulafungin), voriconazole, or lipid formulations of amphotericin B. This may be modified to fluconazole if the sample exhibits sensitivity.
C. krusei exhibits resistance to fluconazole.
C. glabrata frequently exhibits resistance to triazoles.
C. parapsilosis isolates have elevated minimum inhibitory concentrations (MICs) to echinocandins.
C. lusitaniae exhibits resistance to amphotericin B. The advised length of antifungal treatment is a minimum of 2 weeks following the negative results of blood cultures. Verify the implementation of adequate "source control" (e.g., intravenous lines have been removed and substituted).
Esophageal candidiasis: In instances of fluconazole resistance, alternative triazoles, including itraconazole, posaconazole, and voriconazole, shown efficacy. An echinocandin, such as caspofungin, micafungin, or anidulafungin, may be utilized in
Patients who are hospitalized can only receive it in intravenous form.
SUPPLEMENTARY THERAPY
Concerns for Referral
Infectious disease specialists should be sought for bloodstream Candida infections and for guidance in managing neutropenic patients.
Pharmacists are invaluable due to the numerous drug interactions associated with antifungal drugs, particularly the triazoles. Exercise caution when concurrently administering warfarin, rifampin, antiepileptic drugs, and sulfonylureas.
OPERATIONS/ADDITIONAL INTERVENTIONS
A surgical consultation is necessary to drain fluid collections infected with Candida species and to manage candidal endocarditis.
INPATIENT CONSIDERATIONS
Criteria for Admission
Patients suspected with candidemia should be hospitalized and administered empiric antifungal medication.
CONTINUING MANAGEMENT POST-TREATMENT GUIDELINES
Patient Surveillance
QT prolongation must be monitored via ECGs in patients administered triazoles (e.g., fluconazole, voriconazole).
• The pharmacy must evaluate potential drug interactions while administering antifungal medicines, particularly triazoles.
• Conduct daily blood cultures in patients with candidemia to confirm sterilization.
• Ophthalmology should evaluate all patients with candidemia for endophthalmitis.
OUTLOOK
Mortality progressively rises in patients with candidemia who have a delay in antifungal treatment. For instance, individuals treated three or more days after confirmed candidemia exhibit mortality rates above 40%.
COMPLICATIONS • Renal failure • Esophageal perforation • Endocarditis • Endophthalmitis • Meningitis • Peritonitis and adhesions • Pericarditis • Abscess • Mortality
CANDIDIASIS
DESCRIPTION • Candida is a yeast that constitutes part of the normal flora on the skin and within the gastrointestinal and genitourinary tracts. • Candida species are an emerging cause of bloodstream infections in immunocompromised individuals. • Candida can induce both superficial and systemic infections.
Epidemiology: Candidal infections can affect individuals of all ages; however, they are more prevalent among the elderly, babies, and pregnant women.
• A recent study revealed that up to 9% of bloodstream infections in US hospitals were associated with candidal infection.
– Numerous varieties of Candida exist, with Candida albicans being the primary organism associated with the majority of illnesses. Non-albicans Candida species are rising in prevalence. In a recent specimen
Among over 1400 Candida specimens from hospitalized patients, the most prevalent species following C. albicans were C. parapsilosis, C. glabrata, and C. tropicalis.
RISK FACTORS • Immune suppression/neutropenia (2) • Preexisting conditions associated with immune suppression, including cancer, AIDS, and significant burns
• Extended antibiotic administration • Indwelling intravenous catheter • Chemotherapeutic treatment • Recipients of solid organ and bone marrow transplants • Total parenteral nutrition • Chronic renal insufficiency and hemodialysis • Gastrointestinal perforation • Diabetes mellitus • Gestation • Glucocorticoid therapy
GENERAL PREVENTION
• Prudent use of antibiotics. • Extraction of central venous catheters when no longer required.
PATHOPHYSIOLOGY
• Candidemia may arise from disruptions in mucosal barriers at any location within the gastrointestinal system. • Candidemia may also result from the colonization of intravascular catheter devices.
ETIOLOGY • The genus Candida has over 150 species, with the clinically significant species being C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. guilliermondii, and C. lusitaniae. • C. albicans is responsible for over 50% of candidemia cases.
FREQUENTLY CO-OCCURRING CONDITIONS
Immunosuppression due to chemotherapy, HIV/AIDS, solid organ or bone marrow transplantation, neutropenia, or severe underlying conditions necessitating extended ICU admissions with intravenous catheters.
DIAGNOSTIC HISTORY
The clinical presentation and assessment of risk factors are contingent upon the affected organ (e.g., genitourinary and intestinal tracts, brain, skin) and the severity of the disease.
• Vulvovaginal candidiasis: Itching, discomfort, painful urination, painful intercourse, and white, curd-like discharge.
• Oropharyngeal candidiasis: Intermittent discomfort, taste impairment, occasionally asymptomatic.
• Candida esophagitis: Nausea, vomiting, retrosternal chest discomfort, odynophagia, dysphagia.
• Invasive candidiasis: History of immunosuppressive therapy, HIV/AIDS, concomitant malignancy. Mental status alterations may occur if sepsis.
PHYSICAL EXAMINATION
• It is contingent upon the affected organ and the severity of the condition.
• Vulvovaginal candidiasis: Erythema of the vulva or vagina accompanied by a white, curd-like discharge. Occasionally, there is a transparent discharge.
• Oral candidiasis (thrush) and Candida esophagitis: Presence of white plaques on the tongue, hard palate, and soft palate. Frequently results in an erythematous base upon removal. Patients may exhibit esophageal candidiasis in the absence of oral involvement.
Candidemia presents with symptoms ranging from fever to indications of severe sepsis, including hypotension, tachycardia, and alterations in mental status.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• Vulvovaginal candidiasis: Often a clinical diagnosis. The pH of vaginal discharge may vary between 4 and 4.5. Yeast will be observed in microscopic examinations of KOH preparations or wet mounts (3,4).
• Oral candidiasis (thrush): Frequently diagnosed clinically as well. Confirmation can be achieved by examining scrapings on KOH preparations using light microscopy.
Esophageal candidiasis may necessitate endoscopy and biopsy for diagnosis.
Candidemia: Gram staining or proliferation in blood cultures. Candida must not be regarded as a blood contamination.
Susceptibility testing for fluconazole should be conducted in cases of severe infection or in affected people.
ineffective against first-line treatments.
Imaging: Preliminary Strategy
• Neurological assessment: CT scan and MRI of the brain.
• Endocarditis: Transesophageal echocardiography • Esophagitis: Upper endoscopy with biopsy
• Spleen and liver: MRI surpasses CT
Pneumonia: Chest X-ray, Computed Tomography
• Peritonitis: Fluid aspiration guided by CT or ultrasound
Subsequent Actions & Specific Considerations
• For candidemia: Provide general ICU care for stabilization, as death rates may exceed 30–40%.
5–10% of candidemia cases are associated with endophthalmitis complications. Ophthalmology must be consulted in every instance of candidemia.
Diagnostic Procedures/Additional Candida esophagitis: While endoscopy and biopsy represent the definitive method for identifying Candida esophagitis, numerous individuals receive empirical treatment when they exhibit significant symptoms alongside risk factors and oral manifestations.
Candidiasis. It is important to note that oral candidiasis is not a prerequisite for esophageal candidal infections.
Pathological Observations
Yeast exhibiting and lacking pseudohyphae
DIFFERENTIAL DIAGNOSIS
• Oral hairy leukoplakia • Contact dermatitis • Atrophic vaginitis • Bacterial sepsis • Endocarditis • Fever of unknown origin • Cytomegalovirus (CMV) esophagitis
INITIAL THERAPEUTIC AGENT
• Vulvovaginal candidiasis: Various topical treatments are accessible, such as butoconazole cream 5 g/day for 3 days. Oral alternatives are also accessible, including fluconazole 150 mg administered orally as a single dose. Prolonged treatment duration is necessary in severe cases or immunocompromised individuals. Administration of butoconazole cream for 5 to 7 days, or oral fluconazole for up to 7 days, may be required (5–7).
• Oral candidiasis (thrush): Nystatin oral solution (suspension), clotrimazole oral troche, or fluconazole 100–200 mg/day. The therapeutic duration typically spans 5 days following the resolution of symptoms.
Candida esophagitis: Administer Fluconazole 400 mg as a first dose, followed by 200–400 mg daily for a duration of 7–14 days. This can be administered orally, but may be delivered intravenously in certain patients with pronounced dysphagia or odynophagia.
• Candidemia: The selection of empirical therapy is contingent upon the
Candida should undergo culture and sensitivity testing for triazoles (e.g., fluconazole) (8,9). In stable, non-neutropenic patients devoid of antifungal exposure, fluconazole (800 mg intravenously once, followed by 400 mg intravenously daily) is a judicious option. All other patients, including those who are unstable, neutropenic, have prior antifungal exposure, or have experienced recent or extended hospitalizations, should receive empirical treatment with either an echinocandin (caspofungin, micafungin, or anidulafungin), voriconazole, or lipid formulations of amphotericin B. This may be modified to fluconazole if the sample exhibits sensitivity.
C. krusei exhibits resistance to fluconazole.
C. glabrata frequently exhibits resistance to triazoles.
C. parapsilosis isolates have elevated minimum inhibitory concentrations (MICs) to echinocandins.
C. lusitaniae exhibits resistance to amphotericin B. The advised length of antifungal treatment is a minimum of 2 weeks following the negative results of blood cultures. Verify the implementation of adequate "source control" (e.g., intravenous lines have been removed and substituted).
Esophageal candidiasis: In instances of fluconazole resistance, alternative triazoles, including itraconazole, posaconazole, and voriconazole, shown efficacy. An echinocandin, such as caspofungin, micafungin, or anidulafungin, may be utilized in
Patients who are hospitalized can only receive it in intravenous form.
SUPPLEMENTARY THERAPY
Concerns for Referral
Infectious disease specialists should be sought for bloodstream Candida infections and for guidance in managing neutropenic patients.
Pharmacists are invaluable due to the numerous drug interactions associated with antifungal drugs, particularly the triazoles. Exercise caution when concurrently administering warfarin, rifampin, antiepileptic drugs, and sulfonylureas.
OPERATIONS/ADDITIONAL INTERVENTIONS
A surgical consultation is necessary to drain fluid collections infected with Candida species and to manage candidal endocarditis.
INPATIENT CONSIDERATIONS
Criteria for Admission
Patients suspected with candidemia should be hospitalized and administered empiric antifungal medication.
CONTINUING MANAGEMENT POST-TREATMENT GUIDELINES
Patient Surveillance
QT prolongation must be monitored via ECGs in patients administered triazoles (e.g., fluconazole, voriconazole).
• The pharmacy must evaluate potential drug interactions while administering antifungal medicines, particularly triazoles.
• Conduct daily blood cultures in patients with candidemia to confirm sterilization.
• Ophthalmology should evaluate all patients with candidemia for endophthalmitis.
OUTLOOK
Mortality progressively rises in patients with candidemia who have a delay in antifungal treatment. For instance, individuals treated three or more days after confirmed candidemia exhibit mortality rates above 40%.
COMPLICATIONS • Renal failure • Esophageal perforation • Endocarditis • Endophthalmitis • Meningitis • Peritonitis and adhesions • Pericarditis • Abscess • Mortality
- Published on
Infectious Disease – Campylobacter Infections
CAMPYLOBACTER INFECTIONS
BASIC DESCRIPTION
• Campylobacter species are a significant foodborne etiological agent of diarrheal diseases in both developed and developing nations. • Postinfectious sequelae of Campylobacter infection encompass Guillain–Barré syndrome and reactive arthritis.
EPIDEMIOLOGY
Incidence
Campylobacteriosis is a global zoonotic disease, and Campylobacter enteritis is a prevalent kind of acute gastroenteritis in North America.
C. jejuni infections manifest throughout the year in the United States and other industrialized nations, with a pronounced surge during the summer and early autumn months.
• As much as 90% of broiler birds exhibit contamination.
Campylobacter bacteria are readily transmitted by contaminated drinking water and unpasteurized milk. Certain instances are linked to the preparation of contaminated food. However, the epidemiology of the infection in poor nations differs, as C. jejuni is frequently isolated from asymptomatic individuals and is particularly prevalent during the initial five years of life.
RISK FACTORS
In wealthy nations, the intake of undercooked poultry is believed to account for over fifty percent of sporadic Campylobacter infection cases.
HIV-positive individuals exhibit an elevated susceptibility to infections.
Genetics
Reactive arthritis may manifest several weeks after infection in individuals possessing HLA-B27 histocompatibility antigens.
GENERAL PREVENTION • Campylobacter can be eradicated by roasting poultry and other meats to an internal temperature of 82°C (180°F). The temperature at which the meat ceases to exhibit a pink hue and the juices flow clear is specified. Poultry and other meats must be prepared separately from other items, both in commercial establishments and domestic settings.
Countertops, utensils, towels, and aprons utilized in the preparation of chicken and other meats must be cleansed with hot water and soap prior to being employed for other items, especially those that will not undergo cooking.
Handwashing is crucial.
Suspected cases, especially those linked to additional instances within family or acquaintances, must be reported immediately to the local health authority.
Pathophysiology
The incubation period varies from 1 to 7 days.
• A mere 500 germs can induce sickness in certain persons.
The proven correlation between Campylobacter infection and Guillain–Barré syndrome is believed to stem from molecular mimicry, due to the structural similarity of antigens shared by Campylobacter and peripheral nerves.
ETIOLOGY • Campylobacter jejuni and Campylobacter coli are the primary etiological agents of Campylobacter infection in humans.
C. fetus is a significant etiological agent of systemic infection and chronic bacteremia in immunocompromised individuals.
However, it is not a significant cause of enteritis in immunocompetent individuals.
HISTORY OF DIAGNOSIS
• Acute enteritis is the predominant manifestation of C. jejuni infection. • Symptoms may persist for a duration ranging from 1 day to over 1 week.
• Frequently, a prodrome presents with fever, headache, myalgia, and malaise.
• The predominant symptoms are as follows:
- Abdominal discomfort (often cramping) – Diarrhea – Fever (often low-grade but may reach 40°C or higher)
Malaise
• Diarrhea can range from loose stools to profuse watery stools or visibly bloody stools.
• Infections caused by C. fetal might result in intermittent diarrhea or general abdominal discomfort without localized symptoms. • C. fetus may also lead to a lengthy relapsing illness marked by fever, chills, and myalgia, with no identifiable source of infection.
PHYSICAL EXAMINATION
• Physical examination results in the majority of Campylobacter enteritis cases are nonspecific, typically revealing minor abdominal pain.
• In few instances, intense stomach discomfort may cause Campylobacter enteritis to resemble appendicitis (pseudoappendicitis); nevertheless, typical physical indications of peritonitis, such as guarding and rebound soreness, are infrequent.
DIAGNOSTIC TESTS AND INTERPRETATION Lab
In numerous instances of Campylobacter enteritis, a modest leukocytosis accompanied by an elevation in neutrophils is observed.
The diagnosis of Campylobacter jejuni infection is often established through a positive stool culture.
• Campylobacter species are extracted from fecal samples utilizing microaerobic incubation conditions and selective methods that inhibit the proliferation of competing microorganisms. • Bacteremia occurs in less than 1% of individuals with C. jejuni infection.
DIFFERENTIAL DIAGNOSIS
The diagnosis may be inferred from the symptoms.
This can be readily verified using stool culture.
INITIAL THERAPEUTIC AGENT
• Antimicrobial therapy is warranted for individuals with severe or prolonged symptoms, or those with risk factors for consequences, including pregnancy, immunocompromising diseases, or advanced age, as most infections are self-limiting.
Ciprofloxacin (500 mg orally, twice day for 5–7 days) is regarded as a first-line treatment. Nonetheless, the resistance of Campylobacter to quinolones is escalating.
Macrolides, such as erythromycin, represent an additional suitable first-line therapy. The advised dosage for adults is 250 mg orally four times daily for 5–7 days; for children, the suggested dosage is 30–50 mg/kg per day in divided doses for the same duration.
Campylobacter strains obtained in underdeveloped nations exhibit a higher propensity for erythromycin resistance.
The requirement for addressing septic or bacteremic episodes with drugs other than ciprofloxacin has not been determined. For patients with severe toxicity-
Prolonged treatment with gentamicin or imipenem is warranted.
Second Line
Most isolates of C. jejuni and C. coli exhibit resistance to cephalosporins and penicillin; hence, these drugs should be avoided.
• The susceptibility to sulfonamides and metronidazole is inconsistent. Treatment with antimicrobial drugs does not extend the carriage of C. jejuni, unlike Salmonella infections; rather, it typically eradicates carriage within 72 hours in the majority of patients.
SUPPLEMENTARY THERAPY
Comprehensive Strategies
Evaluation of hydration status and suitable fluid and electrolyte replenishment are necessary.
Supplementary Treatments
• The administration of an antimotility agent may extend the duration of symptoms unless it is administered together with an antibiotic. • Antimotility treatments are contraindicated in pediatric patients.
INPATIENT CONSIDERATIONS
Admission Criteria • A limited number of patients with Campylobacter enteritis necessitate hospitalization. • Possible reasons for admission encompass moderate to severe dehydration, intense pain, systemic sickness, or complications (elaborated below).
Intravenous Fluids
Only isotonic solutions should be administered to individuals experiencing severe dehydration.
CONTINUING CARE POST-TREATMENT RECOMMENDATIONS
Postinfectious consequences of Campylobacter enteritis typically manifest within two months following the acute infection.
Patient Surveillance
Patients experiencing recurrent diarrhea should be closely watched through meticulous documentation of fluid intake and output, as well as for indications of dehydration.
DIET
Patients with enteritis may maintain a regular diet as tolerated.
PROGNOSIS
• The majority of patients achieve complete recovery from Campylobacter enteritis, either spontaneously or with suitable antimicrobial treatment.
• Campylobacter infections are the most prevalent.
While Campylobacter enteritis is a well acknowledged antecedent of Guillain–Barré syndrome, it is crucial to note that only 1 in every 1000 people with this condition eventually develops GBS, indicating a minimal risk for any individual.
• Infection with C. fetus may be fatal for individuals with chronic compensated conditions such as cirrhosis or diabetes mellitus.
consequences • The primary postinfectious consequences of Campylobacter enteritis in immunocompetent individuals are reactive arthritis and Guillain–Barré syndrome, as previously mentioned.
• • • • •
Campylobacter infections can be fatal in immunocompromised persons.
Campylobacter jejuni may induce septic abortion.
Reports of C. jejuni infections presenting with acute cholecystitis, pancreatitis, and cystitis have been sporadic.
Campylobacter jejuni has been linked to an intestinal immunoproliferative disease characterized by malabsorption and protein-losing enteropathy.
C. fetal infections demonstrate a preference for arterial locations; vascular necrosis is observed in patients with endocarditis and pericarditis.
CNS infections caused by C. fetus manifest in neonates and
individuals of mature age. The prognosis for premature infants is unfavorable; nonetheless, certain full-term neonates have survived infections. The infection presents as meningoencephalitis characterized by polymorphonuclear pleocytosis in the cerebrospinal fluid.
In immunocompromised patients, particularly those with AIDS, bacteremia caused by the "atypical" Campylobacter species occurs rather frequently and may persist indefinitely in the absence of antibiotic treatment.
CAMPYLOBACTER INFECTIONS
BASIC DESCRIPTION
• Campylobacter species are a significant foodborne etiological agent of diarrheal diseases in both developed and developing nations. • Postinfectious sequelae of Campylobacter infection encompass Guillain–Barré syndrome and reactive arthritis.
EPIDEMIOLOGY
Incidence
Campylobacteriosis is a global zoonotic disease, and Campylobacter enteritis is a prevalent kind of acute gastroenteritis in North America.
C. jejuni infections manifest throughout the year in the United States and other industrialized nations, with a pronounced surge during the summer and early autumn months.
• As much as 90% of broiler birds exhibit contamination.
Campylobacter bacteria are readily transmitted by contaminated drinking water and unpasteurized milk. Certain instances are linked to the preparation of contaminated food. However, the epidemiology of the infection in poor nations differs, as C. jejuni is frequently isolated from asymptomatic individuals and is particularly prevalent during the initial five years of life.
RISK FACTORS
In wealthy nations, the intake of undercooked poultry is believed to account for over fifty percent of sporadic Campylobacter infection cases.
HIV-positive individuals exhibit an elevated susceptibility to infections.
Genetics
Reactive arthritis may manifest several weeks after infection in individuals possessing HLA-B27 histocompatibility antigens.
GENERAL PREVENTION • Campylobacter can be eradicated by roasting poultry and other meats to an internal temperature of 82°C (180°F). The temperature at which the meat ceases to exhibit a pink hue and the juices flow clear is specified. Poultry and other meats must be prepared separately from other items, both in commercial establishments and domestic settings.
Countertops, utensils, towels, and aprons utilized in the preparation of chicken and other meats must be cleansed with hot water and soap prior to being employed for other items, especially those that will not undergo cooking.
Handwashing is crucial.
Suspected cases, especially those linked to additional instances within family or acquaintances, must be reported immediately to the local health authority.
Pathophysiology
The incubation period varies from 1 to 7 days.
• A mere 500 germs can induce sickness in certain persons.
The proven correlation between Campylobacter infection and Guillain–Barré syndrome is believed to stem from molecular mimicry, due to the structural similarity of antigens shared by Campylobacter and peripheral nerves.
ETIOLOGY • Campylobacter jejuni and Campylobacter coli are the primary etiological agents of Campylobacter infection in humans.
C. fetus is a significant etiological agent of systemic infection and chronic bacteremia in immunocompromised individuals.
However, it is not a significant cause of enteritis in immunocompetent individuals.
HISTORY OF DIAGNOSIS
• Acute enteritis is the predominant manifestation of C. jejuni infection. • Symptoms may persist for a duration ranging from 1 day to over 1 week.
• Frequently, a prodrome presents with fever, headache, myalgia, and malaise.
• The predominant symptoms are as follows:
- Abdominal discomfort (often cramping) – Diarrhea – Fever (often low-grade but may reach 40°C or higher)
Malaise
• Diarrhea can range from loose stools to profuse watery stools or visibly bloody stools.
• Infections caused by C. fetal might result in intermittent diarrhea or general abdominal discomfort without localized symptoms. • C. fetus may also lead to a lengthy relapsing illness marked by fever, chills, and myalgia, with no identifiable source of infection.
PHYSICAL EXAMINATION
• Physical examination results in the majority of Campylobacter enteritis cases are nonspecific, typically revealing minor abdominal pain.
• In few instances, intense stomach discomfort may cause Campylobacter enteritis to resemble appendicitis (pseudoappendicitis); nevertheless, typical physical indications of peritonitis, such as guarding and rebound soreness, are infrequent.
DIAGNOSTIC TESTS AND INTERPRETATION Lab
In numerous instances of Campylobacter enteritis, a modest leukocytosis accompanied by an elevation in neutrophils is observed.
The diagnosis of Campylobacter jejuni infection is often established through a positive stool culture.
• Campylobacter species are extracted from fecal samples utilizing microaerobic incubation conditions and selective methods that inhibit the proliferation of competing microorganisms. • Bacteremia occurs in less than 1% of individuals with C. jejuni infection.
DIFFERENTIAL DIAGNOSIS
The diagnosis may be inferred from the symptoms.
This can be readily verified using stool culture.
INITIAL THERAPEUTIC AGENT
• Antimicrobial therapy is warranted for individuals with severe or prolonged symptoms, or those with risk factors for consequences, including pregnancy, immunocompromising diseases, or advanced age, as most infections are self-limiting.
Ciprofloxacin (500 mg orally, twice day for 5–7 days) is regarded as a first-line treatment. Nonetheless, the resistance of Campylobacter to quinolones is escalating.
Macrolides, such as erythromycin, represent an additional suitable first-line therapy. The advised dosage for adults is 250 mg orally four times daily for 5–7 days; for children, the suggested dosage is 30–50 mg/kg per day in divided doses for the same duration.
Campylobacter strains obtained in underdeveloped nations exhibit a higher propensity for erythromycin resistance.
The requirement for addressing septic or bacteremic episodes with drugs other than ciprofloxacin has not been determined. For patients with severe toxicity-
Prolonged treatment with gentamicin or imipenem is warranted.
Second Line
Most isolates of C. jejuni and C. coli exhibit resistance to cephalosporins and penicillin; hence, these drugs should be avoided.
• The susceptibility to sulfonamides and metronidazole is inconsistent. Treatment with antimicrobial drugs does not extend the carriage of C. jejuni, unlike Salmonella infections; rather, it typically eradicates carriage within 72 hours in the majority of patients.
SUPPLEMENTARY THERAPY
Comprehensive Strategies
Evaluation of hydration status and suitable fluid and electrolyte replenishment are necessary.
Supplementary Treatments
• The administration of an antimotility agent may extend the duration of symptoms unless it is administered together with an antibiotic. • Antimotility treatments are contraindicated in pediatric patients.
INPATIENT CONSIDERATIONS
Admission Criteria • A limited number of patients with Campylobacter enteritis necessitate hospitalization. • Possible reasons for admission encompass moderate to severe dehydration, intense pain, systemic sickness, or complications (elaborated below).
Intravenous Fluids
Only isotonic solutions should be administered to individuals experiencing severe dehydration.
CONTINUING CARE POST-TREATMENT RECOMMENDATIONS
Postinfectious consequences of Campylobacter enteritis typically manifest within two months following the acute infection.
Patient Surveillance
Patients experiencing recurrent diarrhea should be closely watched through meticulous documentation of fluid intake and output, as well as for indications of dehydration.
DIET
Patients with enteritis may maintain a regular diet as tolerated.
PROGNOSIS
• The majority of patients achieve complete recovery from Campylobacter enteritis, either spontaneously or with suitable antimicrobial treatment.
• Campylobacter infections are the most prevalent.
While Campylobacter enteritis is a well acknowledged antecedent of Guillain–Barré syndrome, it is crucial to note that only 1 in every 1000 people with this condition eventually develops GBS, indicating a minimal risk for any individual.
• Infection with C. fetus may be fatal for individuals with chronic compensated conditions such as cirrhosis or diabetes mellitus.
consequences • The primary postinfectious consequences of Campylobacter enteritis in immunocompetent individuals are reactive arthritis and Guillain–Barré syndrome, as previously mentioned.
• • • • •
Campylobacter infections can be fatal in immunocompromised persons.
Campylobacter jejuni may induce septic abortion.
Reports of C. jejuni infections presenting with acute cholecystitis, pancreatitis, and cystitis have been sporadic.
Campylobacter jejuni has been linked to an intestinal immunoproliferative disease characterized by malabsorption and protein-losing enteropathy.
C. fetal infections demonstrate a preference for arterial locations; vascular necrosis is observed in patients with endocarditis and pericarditis.
CNS infections caused by C. fetus manifest in neonates and
individuals of mature age. The prognosis for premature infants is unfavorable; nonetheless, certain full-term neonates have survived infections. The infection presents as meningoencephalitis characterized by polymorphonuclear pleocytosis in the cerebrospinal fluid.
In immunocompromised patients, particularly those with AIDS, bacteremia caused by the "atypical" Campylobacter species occurs rather frequently and may persist indefinitely in the absence of antibiotic treatment.
- Published on
Infectious Disease- Coccidioiddomycosis
COCCIDIOIDDOMYCOSIS
ESSENTIALS DESCRIPTION
The dimorphic fungus Coccidioides immitis is the cause of pulmonary and/or extrapulmonary infections caused by coccidioidomycosis.
The incidence of epidemiology • There are roughly 91 instances of coccidioidomycosis for every 100,000 people in the United States. throughout addition to Mexico and Central and South America, C. immitis is endemic throughout the southwestern United States (primarily California, Arizona, and Texas). More and more cases are being identified outside of the endemic areas (travelers or reactivations). • The number of patients grows sharply on a periodic basis.
RISK ELEMENTS
Due to the possibility of late recrudescence of latent infection, patients with immunosuppressive diseases or treatments, such as AIDS, solid-organ transplantation, or lymphoma, should be mindful of even remote exposure to endemic areas. Patients with AIDS who have CD4 counts below 250 cells/mm3 are at a higher risk of developing coccidioidomycosis. Although the precise amount of steroids that indicates an elevated risk has not been determined, patients undergoing immunosuppressive and glucocorticoid therapy are more susceptible to coccidioidomycosis.
PATHOPHYSIOLOGY
A progressive pneumonia or chronic lung infection may occur if the acute pulmonary infection does not go away
• Antifungal treatment should be administered to patients having a history of coccidioidomycosis at the time of engraftment, regardless of whether they are currently infected, according to experience with organ transplantation. Even asymptomatic seropositive transplant recipients should get antifungal treatment during acute rejection episodes.
ETIOLOGY • C. immitis is a soil-dwelling fungus that thrives at 27°C, while 30°C is the ideal temperature for its growth.
COMMON CONNECTED CIRCUMSTANCES
Usually referred to as "Valley fever," this condition can affect immunocompetent persons and more invasively affect immunocompromised patients. History of Diagnosis • One to three weeks following exposure, symptoms appear. A lower respiratory infection with systemic symptoms like the following is the usual presentation: Sputum production, fever, coughing, chest pain, anorexia, and arthritis Sweating; weakness; the development of erythema nodosum or erythema multiforme. • Asymptomatic residual illness in the lungs, typically nodules or thin-walled cavities, affects approximately 5% of infected individuals. • Approximately one out of every 200 individuals infected with C. immitis develops symptomatic extrapulmonary illness. The skin, soft tissues, bone and joints, and meninges are the typical locations. • If immunity is compromised by medicine or illness, sickness outside the lungs may manifest considerably later than the typical one-year period following the original infection. • Although there are many different types of skin involvement, wart-like nodules are the most prevalent. • More than 90% of individuals with joint involvement have unilateral joint lesions.
MEDICAL EXAMINATION
The skin and nerve system should receive particular attention for any involvement. • Since coccidioidal lesions are frequently focused and generate localized symptoms like discomfort, swelling, or ulceration, a thorough evaluation of symptoms and physical examination are usually sufficient to identify the presence of an extrapulmonary infection.
Diagnostic Examination and Interpretation Laboratory
• When a lung nodule is removed due to probable cancer in endemic locations, a history of C. immitis infection is often identified. • Accurate travel history collection is essential for timely detection of coccidioidal illness in patients who are not in endemic areas. Culture, serologic testing, and a positive coccidioidal skin test are the cornerstones of diagnosis. Experienced labs are the ideal places to do serologic testing. In 75% of patients with initial infections, serum IgM antibodies can be momentarily identified. If the illness goes away, the IgG antibody, which is present later, normally goes away in a few months. Seldom do serologic testing result in false positives. Nearly all patients with primary infections have positive skin-test reactions to coccidioidal antigens shortly after symptoms appear, and cross-reactions with other illnesses are uncommon. Patients with primary infections frequently do not have cultures, despite the fact that they are frequently used to diagnosis coccidioidomycosis in patients with disseminated infections. The basilar meninges are typically affected by meningitis. When the CSF fluid is examined, it reveals mononuclear pleocytosis, low glucose, and high protein levels.
Imagining
Hilar adenopathy, a pleural effusion, and infiltrates are possible radiographic findings of the chest. Diabetes, immunosuppressive illnesses or treatments, and late-stage pregnancy are associated ailments that are especially significant risk factors. Lung cancer and other widespread fungal infections are examples of differential diagnosis. First Line of Treatment Medication • Because controlled comparisons between antifungal and placebo regimens have not been conducted, the role of antifungal medication in individuals with mild or severe early infection symptoms is not well established
• Therapy might speed up the resolution of symptoms. Therefore, doctors should determine if a patient's situation calls for treatment with the available oral antifungal drugs on a case-by-case basis
• If treatment is started, 400 mg/d of fluconazole and 200 mg twice daily of itraconazole are appropriate dosing. Generally speaking, recommended therapy courses last three to six months. • The following are some factors that should be considered in favor of therapy: A negative skin test; conditions indicating a high fungal inoculum; and concurrent noncoccidioidal disease Increased host sensitivity, incapacity to function, elevated antibody titers, and infiltrations involving more than half of a lung - Severe night sweats that last more than three weeks - Weight loss of more than 10% Silar adenopathy that is noticeable or chronic; symptoms that last longer than two months
• Prolonged chemotherapy is always recommended for individuals with disseminated illness. • During chemotherapy, pulmonary resection can be used to treat severe hemoptysis or cavities that burst or expand. In order to empty empyemas, seal persistent bronchopleural fistulas, or enlarge lungs that are constrained by lingering illness, surgery may also be necessary. • The preferred medications for treating meningeal illness are fluconazole and itraconazole. • The fact that azole therapy is well tolerated, does not have the toxic effects of amphotericin B, and does not require administration into the cerebrospinal fluid may represent significant advantages in patients with an otherwise fatal illness, even if C. immitis infection cannot be cured and lifelong suppression is necessary. Line Two Chemotherapy is nearly usually recommended once the illness has progressed outside of the lungs. Patients who do not respond to azole treatment are treated with amphotericin B.
PERMANENT CARE FOLLOW-UP ADVICE
• Residual sequelae, many of which have minimal long-term effects, are caused by 5–10% of infections. • The serologic response to C. immitis is typically at least qualitatively intact in those who are more susceptible to infection. The doctor should be aware of the probability of this diagnosis if the patient has a history of travel or residency in endemic areas. A postponed diagnosis can be avoided with routine serologic testing. • Ninety percent of meningitis patients die within a year if treatment is not received, thus early detection is crucial. • Some individuals develop chronic lung disease as a result of their acute pneumonia, which never goes away. This group is disproportionately overrepresented among individuals with diabetes and those with weakened immune systems.
COMPLICATIONS
• Immunocompromised people are more susceptible to the disease, especially if they have extrapulmonary coccidioidal disease. The first year following an organ transplant is the time when patients are most vulnerable to infection. • Meningitis may manifest clinically practically simultaneously with the initial infection and typically develops 6 months after it. Typically, there are no symptoms of meningeal irritation that are typical with bacterial meningitis. The headache is the most typical symptom. There may be focal neurologic problems, fever, weakness, disorientation, sluggishness, seizures, aberrant behavior, stiff neck, diplopia, ataxia, and vomiting.
COCCIDIOIDDOMYCOSIS
ESSENTIALS DESCRIPTION
The dimorphic fungus Coccidioides immitis is the cause of pulmonary and/or extrapulmonary infections caused by coccidioidomycosis.
The incidence of epidemiology • There are roughly 91 instances of coccidioidomycosis for every 100,000 people in the United States. throughout addition to Mexico and Central and South America, C. immitis is endemic throughout the southwestern United States (primarily California, Arizona, and Texas). More and more cases are being identified outside of the endemic areas (travelers or reactivations). • The number of patients grows sharply on a periodic basis.
RISK ELEMENTS
Due to the possibility of late recrudescence of latent infection, patients with immunosuppressive diseases or treatments, such as AIDS, solid-organ transplantation, or lymphoma, should be mindful of even remote exposure to endemic areas. Patients with AIDS who have CD4 counts below 250 cells/mm3 are at a higher risk of developing coccidioidomycosis. Although the precise amount of steroids that indicates an elevated risk has not been determined, patients undergoing immunosuppressive and glucocorticoid therapy are more susceptible to coccidioidomycosis.
PATHOPHYSIOLOGY
A progressive pneumonia or chronic lung infection may occur if the acute pulmonary infection does not go away
• Antifungal treatment should be administered to patients having a history of coccidioidomycosis at the time of engraftment, regardless of whether they are currently infected, according to experience with organ transplantation. Even asymptomatic seropositive transplant recipients should get antifungal treatment during acute rejection episodes.
ETIOLOGY • C. immitis is a soil-dwelling fungus that thrives at 27°C, while 30°C is the ideal temperature for its growth.
COMMON CONNECTED CIRCUMSTANCES
Usually referred to as "Valley fever," this condition can affect immunocompetent persons and more invasively affect immunocompromised patients. History of Diagnosis • One to three weeks following exposure, symptoms appear. A lower respiratory infection with systemic symptoms like the following is the usual presentation: Sputum production, fever, coughing, chest pain, anorexia, and arthritis Sweating; weakness; the development of erythema nodosum or erythema multiforme. • Asymptomatic residual illness in the lungs, typically nodules or thin-walled cavities, affects approximately 5% of infected individuals. • Approximately one out of every 200 individuals infected with C. immitis develops symptomatic extrapulmonary illness. The skin, soft tissues, bone and joints, and meninges are the typical locations. • If immunity is compromised by medicine or illness, sickness outside the lungs may manifest considerably later than the typical one-year period following the original infection. • Although there are many different types of skin involvement, wart-like nodules are the most prevalent. • More than 90% of individuals with joint involvement have unilateral joint lesions.
MEDICAL EXAMINATION
The skin and nerve system should receive particular attention for any involvement. • Since coccidioidal lesions are frequently focused and generate localized symptoms like discomfort, swelling, or ulceration, a thorough evaluation of symptoms and physical examination are usually sufficient to identify the presence of an extrapulmonary infection.
Diagnostic Examination and Interpretation Laboratory
• When a lung nodule is removed due to probable cancer in endemic locations, a history of C. immitis infection is often identified. • Accurate travel history collection is essential for timely detection of coccidioidal illness in patients who are not in endemic areas. Culture, serologic testing, and a positive coccidioidal skin test are the cornerstones of diagnosis. Experienced labs are the ideal places to do serologic testing. In 75% of patients with initial infections, serum IgM antibodies can be momentarily identified. If the illness goes away, the IgG antibody, which is present later, normally goes away in a few months. Seldom do serologic testing result in false positives. Nearly all patients with primary infections have positive skin-test reactions to coccidioidal antigens shortly after symptoms appear, and cross-reactions with other illnesses are uncommon. Patients with primary infections frequently do not have cultures, despite the fact that they are frequently used to diagnosis coccidioidomycosis in patients with disseminated infections. The basilar meninges are typically affected by meningitis. When the CSF fluid is examined, it reveals mononuclear pleocytosis, low glucose, and high protein levels.
Imagining
Hilar adenopathy, a pleural effusion, and infiltrates are possible radiographic findings of the chest. Diabetes, immunosuppressive illnesses or treatments, and late-stage pregnancy are associated ailments that are especially significant risk factors. Lung cancer and other widespread fungal infections are examples of differential diagnosis. First Line of Treatment Medication • Because controlled comparisons between antifungal and placebo regimens have not been conducted, the role of antifungal medication in individuals with mild or severe early infection symptoms is not well established
• Therapy might speed up the resolution of symptoms. Therefore, doctors should determine if a patient's situation calls for treatment with the available oral antifungal drugs on a case-by-case basis
• If treatment is started, 400 mg/d of fluconazole and 200 mg twice daily of itraconazole are appropriate dosing. Generally speaking, recommended therapy courses last three to six months. • The following are some factors that should be considered in favor of therapy: A negative skin test; conditions indicating a high fungal inoculum; and concurrent noncoccidioidal disease Increased host sensitivity, incapacity to function, elevated antibody titers, and infiltrations involving more than half of a lung - Severe night sweats that last more than three weeks - Weight loss of more than 10% Silar adenopathy that is noticeable or chronic; symptoms that last longer than two months
• Prolonged chemotherapy is always recommended for individuals with disseminated illness. • During chemotherapy, pulmonary resection can be used to treat severe hemoptysis or cavities that burst or expand. In order to empty empyemas, seal persistent bronchopleural fistulas, or enlarge lungs that are constrained by lingering illness, surgery may also be necessary. • The preferred medications for treating meningeal illness are fluconazole and itraconazole. • The fact that azole therapy is well tolerated, does not have the toxic effects of amphotericin B, and does not require administration into the cerebrospinal fluid may represent significant advantages in patients with an otherwise fatal illness, even if C. immitis infection cannot be cured and lifelong suppression is necessary. Line Two Chemotherapy is nearly usually recommended once the illness has progressed outside of the lungs. Patients who do not respond to azole treatment are treated with amphotericin B.
PERMANENT CARE FOLLOW-UP ADVICE
• Residual sequelae, many of which have minimal long-term effects, are caused by 5–10% of infections. • The serologic response to C. immitis is typically at least qualitatively intact in those who are more susceptible to infection. The doctor should be aware of the probability of this diagnosis if the patient has a history of travel or residency in endemic areas. A postponed diagnosis can be avoided with routine serologic testing. • Ninety percent of meningitis patients die within a year if treatment is not received, thus early detection is crucial. • Some individuals develop chronic lung disease as a result of their acute pneumonia, which never goes away. This group is disproportionately overrepresented among individuals with diabetes and those with weakened immune systems.
COMPLICATIONS
• Immunocompromised people are more susceptible to the disease, especially if they have extrapulmonary coccidioidal disease. The first year following an organ transplant is the time when patients are most vulnerable to infection. • Meningitis may manifest clinically practically simultaneously with the initial infection and typically develops 6 months after it. Typically, there are no symptoms of meningeal irritation that are typical with bacterial meningitis. The headache is the most typical symptom. There may be focal neurologic problems, fever, weakness, disorientation, sluggishness, seizures, aberrant behavior, stiff neck, diplopia, ataxia, and vomiting.
- Published on
CHRONIC FATIGUE SYNDROME
BASICS DESCRIPTION: Chronic fatigue syndrome (CFS) is a diverse condition that causes extreme, incapacitating fatigue that lasts for at least six months.
Considerations for Children
• Seldom seen in kids.
• As the counterpart of an adult handicap, absenteeism from activities or school should be tracked.
The study of epidemiology
In the US, the prevalence ranges from 4.0 to 8.7 per 100,000 (2). • Prevalence: 0.6–1% globally.
RISK ELEMENTS
Gender: women are 2-3 times more likely to have it. Genetics
ongoing investigation to see if any particular genes are connected to CFS.
Pathophysiology
Not sure.
ETIOLOGY: Unknown.
• There have been hypothesized but unsubstantiated correlations with EBV, CMV, HHV, HCV, Borrelia burgdorferi, and Brucella.
• Possible links to immunological or neuroendocrine conditions, including those involving the autonomic nervous system or the hypothalamic-pituitary-adrenal axis.
COMMON CONNECTED CIRCUMSTANCES
Depressive symptoms and fibromyalgia
History of Diagnosis
• Severe exhaustion that has persisted for over six months and has not gone away with rest.
• Four of the symptoms listed below:
Post-exercise malaise: Sleep that doesn't alleviate weariness
A diminished capacity for memory or focus
Muscle pain; joint pain in several places without heat or swelling; cervical or axillary lymph node pain; sore throat; headache
PHYSICAL EXAMINATION: Although it is possible, painful lymphadenopathy is not necessary for diagnosis.
• Minimal outward signs.
TESTS FOR DIAGNOSIS AND INTERPRETATION
Lab
as required to take into account additional causes of weariness.
Imagining
Not advised.
Diagnostic Techniques and Other
clinical history-based diagnosis of exclusion, in accordance with the 1994 CDC criteria.
There are no pathological findings.
DIFFERENTIAL DIAGNOSIS: Lyme disease, depression, epilepsy, brucellosis, CMV, Epstein-Barr virus, and HIV infection
Brain tumors, tumors with paraneoplastic syndrome, and collagen-vascular diseases
MEDICAL CARE
supportive actions listed below.
MEDICATION Antidepressants along with other forms of treatment.
ADDITIONAL MEDICATION
Overall Actions
a focus on several treatment approaches with the aim of gradual progress over time.
Other Treatments
CBT, or cognitive behavioral treatment, is one (1) example.
A regimen called graded exercise treatment helps people with CFS avoid the "push-crash" cycle, which is characterized by overexertion followed by post-exertional malaise.
Throughout the day, schedule shorter bursts of moderate activity to lower the risk of "push-
crash" cycle. combines exercise and cognitive behavioral therapy. • Good sleep habits.
• Research on sleep.
ALTERNATIVE AND COMPLIMENTARY THERAPIES
• Deep breathing and other relaxing methods; • Massage Tai chi, yoga, and healing touch
Continuing Care Follow-Up Suggestions
It is advised to follow up with a multidisciplinary team of providers on a regular basis.
PROGNOSIS
• It takes a long time to get diagnosed (around five years on average). • Symptom improvement: 6–63%.
• Symptom resolution: 0–37%.
BASICS DESCRIPTION: Chronic fatigue syndrome (CFS) is a diverse condition that causes extreme, incapacitating fatigue that lasts for at least six months.
Considerations for Children
• Seldom seen in kids.
• As the counterpart of an adult handicap, absenteeism from activities or school should be tracked.
The study of epidemiology
In the US, the prevalence ranges from 4.0 to 8.7 per 100,000 (2). • Prevalence: 0.6–1% globally.
RISK ELEMENTS
Gender: women are 2-3 times more likely to have it. Genetics
ongoing investigation to see if any particular genes are connected to CFS.
Pathophysiology
Not sure.
ETIOLOGY: Unknown.
• There have been hypothesized but unsubstantiated correlations with EBV, CMV, HHV, HCV, Borrelia burgdorferi, and Brucella.
• Possible links to immunological or neuroendocrine conditions, including those involving the autonomic nervous system or the hypothalamic-pituitary-adrenal axis.
COMMON CONNECTED CIRCUMSTANCES
Depressive symptoms and fibromyalgia
History of Diagnosis
• Severe exhaustion that has persisted for over six months and has not gone away with rest.
• Four of the symptoms listed below:
Post-exercise malaise: Sleep that doesn't alleviate weariness
A diminished capacity for memory or focus
Muscle pain; joint pain in several places without heat or swelling; cervical or axillary lymph node pain; sore throat; headache
PHYSICAL EXAMINATION: Although it is possible, painful lymphadenopathy is not necessary for diagnosis.
• Minimal outward signs.
TESTS FOR DIAGNOSIS AND INTERPRETATION
Lab
as required to take into account additional causes of weariness.
Imagining
Not advised.
Diagnostic Techniques and Other
clinical history-based diagnosis of exclusion, in accordance with the 1994 CDC criteria.
There are no pathological findings.
DIFFERENTIAL DIAGNOSIS: Lyme disease, depression, epilepsy, brucellosis, CMV, Epstein-Barr virus, and HIV infection
Brain tumors, tumors with paraneoplastic syndrome, and collagen-vascular diseases
MEDICAL CARE
supportive actions listed below.
MEDICATION Antidepressants along with other forms of treatment.
ADDITIONAL MEDICATION
Overall Actions
a focus on several treatment approaches with the aim of gradual progress over time.
Other Treatments
CBT, or cognitive behavioral treatment, is one (1) example.
A regimen called graded exercise treatment helps people with CFS avoid the "push-crash" cycle, which is characterized by overexertion followed by post-exertional malaise.
Throughout the day, schedule shorter bursts of moderate activity to lower the risk of "push-
crash" cycle. combines exercise and cognitive behavioral therapy. • Good sleep habits.
• Research on sleep.
ALTERNATIVE AND COMPLIMENTARY THERAPIES
• Deep breathing and other relaxing methods; • Massage Tai chi, yoga, and healing touch
Continuing Care Follow-Up Suggestions
It is advised to follow up with a multidisciplinary team of providers on a regular basis.
PROGNOSIS
• It takes a long time to get diagnosed (around five years on average). • Symptom improvement: 6–63%.
• Symptom resolution: 0–37%.
- Published on
Infectious Disease -Cholera
ESSENTIAL DETAILS
high levels of watery diarrhea brought on by Vibrio cholerae. The study of epidemiology
The prevalence
Per WHO (2010), there are 3–5 million cases annually (2).
• Every year, 100,000–120,000 people die.
• The second leading cause of death globally for children under five.
RISK ELEMENTS
• The clinical course is more severe in immunocompromised people.
• Undernourishment.
• The El Tor subtype puts blood group O at risk for serious illness.
· Being exposed to epidemics or endemic environments.
Considerations for Pregnancy
higher chance of miscarriage or early birth (patients in the third trimester had a 50% chance).
OVERALL PREVENTION
• Bringing water to a boil or using chlorine, iodine, or filtration.
• Hand washing.
The WHO recommends vaccination with the killed-whole cell vaccine (rBS-WC). short-lived (~2 years), but has shown 78% protection in endemic areas (2).
In areas where cholera is endemic, 50% immunization may result in a 93% decrease in cases, demonstrating the protective effect of herd immunity (1).
Pathophysiology
• Fecal–oral infection, usually from tainted food, water, or raw seafood.
• The cholera toxin has one A subunit and five B subunits, which bind to enterocytes and enhance the outflow of chloride ions.
12 hours to 5 days is the incubation period. In high inoculum and high-gastric pH, it can happen in a matter of hours.
Ethiology
• The gram-negative rod V. cholerae.
• O-Antigen defines 190 serotypes.
• The epidemic strains are only produced by O1 (either El Tor or classical) and O139; non-O strains cause a moderate case of diarrhea.
History of Diagnosis
• Mucus-filled watery diarrhea, sometimes referred to as "rice water stools," which frequently have a "fishy" smell (1).
• Diarrhea may be more than one liter per hour (cholera gravis).
• No fever; cramping in the abdomen, usually without discomfort.
MEDICAL EXAMINATION
Dehydration: Reduced turgor of the skin.
Tests for Diagnosis and Interpretation
Initial laboratory tests
• Glucose and electrolytes The function of the kidneys
Follow-up and Particular Points to Remember
careful observation of volume status, electrolyte losses, and acidosis.
Diagnostic Techniques and Other
Motile gram-negative rods, or stool gram stain.
• Stool culture (on selective medium like modified gelatin taurocholate tellurite agar (TTGA) or Thiosulfate Citrate Bile Sucrose Agar (TCBS).
DIFFERENTIAL DIAGNOSIS: Shigellosis, Salmonellosis, Enterotoxigenic Escherichia coli, and Viral gastroenteritis (e.g., rotavirus)
MEDICATION FOR TREATMENT
Supplementary to rehydration (1).
• Administered when PO is tolerated; earlier IV treatment is not beneficial.
• Antibiotic use will reduce Vibrio excretion (to 1 day) and stool production (by approximately 50%).
First Phrase
Doxycycline 300 mg p.o. × 1 dose; Tetracycline 500 mg p.o. q.i.d. × 3 days
Line Two
Ciprofloxacin 250 mg p.o. b.i.d. × 3 days or 1 g p.o. × 1 dosage; Norfloxacin 400 mg p.o. b.i.d. × 3 days; Azithromycin 1 g p.o. × 1 dose
Considerations for Children
• Steer clear of tetracyclines and quinolones.
• Rx: 20 mg/kg p.o. × 1 dose or erythromycin 12.5 mg/kg p.o. t.i.d. × 3 days
Considerations for Pregnancy
The same care is given as to children.
ADDITIONAL MEDICATION
Overall Actions
Solutions for oral rehydration: The gut will absorb water, glucose, and salt even in the presence of cholera toxin.
Referral Issues
if the patient is unable to take PO (because to vomiting or a change in mental condition, for example) or if dehydration has caused the loss of more than 10% of body weight.
Other Treatments
• It has been demonstrated that taking 30 mg of zinc orally every day reduces the amount of feces produced and the length of diarrhea (3).
• Worries about growing resistance (e.g., multiply antibiotic-resistant V. cholerae O1, gyrA, MARV,
parC).
Considering the patient
First Stabilization
• Hydration.
• Vigilant observation of hyperglycemia, acidosis, and electrolytes.
• Hydration therapy shouldn't be started pending a confirmed diagnosis.
Requirements for Admission
• Although rare, hypoglycemia is a poor prognostic indication. • Unable to accept PO.
Intravenous Fluids
• Should PO not be accepted.
• Base and potassium (such as lactated ringers) should be isotonic.
Criteria for Discharge
the capacity to accept sufficient POs.
Continuing Care Follow-Up Suggestions
If one member of a family of five is afflicted, household contacts should receive antibiotic prophylaxis (WHO) (2).
Monitoring of Patients
Diarrhea can continue four to six days, with the first two days usually being the worst.
No need to relax the belly; eat as tolerated.
PATIENT EDUCATION: Unlike Salmonella, many carriers are asymptomatic but short-term and low inoculum.
• Hand washing.
PROGNOSIS: Oral hydration alone is effective in 80% of instances.
• If left untreated, 50% of people die.
DIFFICULTIES
• Electrolyte imbalance-related arrhythmias. • Failure of the kidneys.
ESSENTIAL DETAILS
high levels of watery diarrhea brought on by Vibrio cholerae. The study of epidemiology
The prevalence
Per WHO (2010), there are 3–5 million cases annually (2).
• Every year, 100,000–120,000 people die.
• The second leading cause of death globally for children under five.
RISK ELEMENTS
• The clinical course is more severe in immunocompromised people.
• Undernourishment.
• The El Tor subtype puts blood group O at risk for serious illness.
· Being exposed to epidemics or endemic environments.
Considerations for Pregnancy
higher chance of miscarriage or early birth (patients in the third trimester had a 50% chance).
OVERALL PREVENTION
• Bringing water to a boil or using chlorine, iodine, or filtration.
• Hand washing.
The WHO recommends vaccination with the killed-whole cell vaccine (rBS-WC). short-lived (~2 years), but has shown 78% protection in endemic areas (2).
In areas where cholera is endemic, 50% immunization may result in a 93% decrease in cases, demonstrating the protective effect of herd immunity (1).
Pathophysiology
• Fecal–oral infection, usually from tainted food, water, or raw seafood.
• The cholera toxin has one A subunit and five B subunits, which bind to enterocytes and enhance the outflow of chloride ions.
12 hours to 5 days is the incubation period. In high inoculum and high-gastric pH, it can happen in a matter of hours.
Ethiology
• The gram-negative rod V. cholerae.
• O-Antigen defines 190 serotypes.
• The epidemic strains are only produced by O1 (either El Tor or classical) and O139; non-O strains cause a moderate case of diarrhea.
History of Diagnosis
• Mucus-filled watery diarrhea, sometimes referred to as "rice water stools," which frequently have a "fishy" smell (1).
• Diarrhea may be more than one liter per hour (cholera gravis).
• No fever; cramping in the abdomen, usually without discomfort.
MEDICAL EXAMINATION
Dehydration: Reduced turgor of the skin.
Tests for Diagnosis and Interpretation
Initial laboratory tests
• Glucose and electrolytes The function of the kidneys
Follow-up and Particular Points to Remember
careful observation of volume status, electrolyte losses, and acidosis.
Diagnostic Techniques and Other
Motile gram-negative rods, or stool gram stain.
• Stool culture (on selective medium like modified gelatin taurocholate tellurite agar (TTGA) or Thiosulfate Citrate Bile Sucrose Agar (TCBS).
DIFFERENTIAL DIAGNOSIS: Shigellosis, Salmonellosis, Enterotoxigenic Escherichia coli, and Viral gastroenteritis (e.g., rotavirus)
MEDICATION FOR TREATMENT
Supplementary to rehydration (1).
• Administered when PO is tolerated; earlier IV treatment is not beneficial.
• Antibiotic use will reduce Vibrio excretion (to 1 day) and stool production (by approximately 50%).
First Phrase
Doxycycline 300 mg p.o. × 1 dose; Tetracycline 500 mg p.o. q.i.d. × 3 days
Line Two
Ciprofloxacin 250 mg p.o. b.i.d. × 3 days or 1 g p.o. × 1 dosage; Norfloxacin 400 mg p.o. b.i.d. × 3 days; Azithromycin 1 g p.o. × 1 dose
Considerations for Children
• Steer clear of tetracyclines and quinolones.
• Rx: 20 mg/kg p.o. × 1 dose or erythromycin 12.5 mg/kg p.o. t.i.d. × 3 days
Considerations for Pregnancy
The same care is given as to children.
ADDITIONAL MEDICATION
Overall Actions
Solutions for oral rehydration: The gut will absorb water, glucose, and salt even in the presence of cholera toxin.
Referral Issues
if the patient is unable to take PO (because to vomiting or a change in mental condition, for example) or if dehydration has caused the loss of more than 10% of body weight.
Other Treatments
• It has been demonstrated that taking 30 mg of zinc orally every day reduces the amount of feces produced and the length of diarrhea (3).
• Worries about growing resistance (e.g., multiply antibiotic-resistant V. cholerae O1, gyrA, MARV,
parC).
Considering the patient
First Stabilization
• Hydration.
• Vigilant observation of hyperglycemia, acidosis, and electrolytes.
• Hydration therapy shouldn't be started pending a confirmed diagnosis.
Requirements for Admission
• Although rare, hypoglycemia is a poor prognostic indication. • Unable to accept PO.
Intravenous Fluids
• Should PO not be accepted.
• Base and potassium (such as lactated ringers) should be isotonic.
Criteria for Discharge
the capacity to accept sufficient POs.
Continuing Care Follow-Up Suggestions
If one member of a family of five is afflicted, household contacts should receive antibiotic prophylaxis (WHO) (2).
Monitoring of Patients
Diarrhea can continue four to six days, with the first two days usually being the worst.
No need to relax the belly; eat as tolerated.
PATIENT EDUCATION: Unlike Salmonella, many carriers are asymptomatic but short-term and low inoculum.
• Hand washing.
PROGNOSIS: Oral hydration alone is effective in 80% of instances.
• If left untreated, 50% of people die.
DIFFICULTIES
• Electrolyte imbalance-related arrhythmias. • Failure of the kidneys.
- Published on
Infectious Disease - Cholangitis/Cholecystitis
DESCRIPTION: Cholangitis is a clinical diagnosis based on symptoms and indicators of systemic sepsis that originate in the biliary tract, while cholecystitis is an acute or chronic inflammation of the gallbladder.
• Gallbladder inflammation, also known as gaseous cholecystitis, is typified by gas in the gallbladder lumen that may penetrate the gallbladder wall and/or surrounding tissues.
EPIDEMIOLOGY • Three to ten percent of patients with stomach pain have acute cholecystitis. In patients older than 50, the frequency rises to 20%.
• Biliary colic affects 1–4% of cholelithiasis patients each year. Twenty percent of people with symptoms go on to develop acute cholecystitis if they are not treated.
RISK ELEMENTS
• Cholelithiasis is the cause of 90–95% of acute cholecystitis cases.
• The risk of cholelithiasis and cholecystitis is elevated by both obesity and severe dieting.
• Hemolytic disorders, such as sickle cell disease and G6PD deficiency, raise the incidence of pigment stones and the biliary blockage that follows.
• Some ethnic groups, like Pima Indians, are more likely to experience stone formation.
Diabetes mellitus, ischemia, sepsis, and other low-flow states; motility disorders; severe burns or trauma; direct chemical injury; allergic reactions; prolonged use of total parenteral nutrition; vasculitis; collagen disease; sarcoidosis; infections (such as TB, actinomycosis, ascariasis, and HIV/AIDS); and gallbladder torsion are all linked to acalculous cholecystitis.
– In AIDS patients, acalculous cholecystitis usually develops earlier in life and is linked to infections with the cytomegalovirus (CMV) and cryptosporidium.
• Patients with diabetes mellitus and the elderly are more likely to develop emphysematous cholecystitis.
• An infectious consequence of retrograde endoscopic cholangiopancreatography (ERCP).
Considerations for Pregnancy
Although cholelithiasis is common during pregnancy, it is unknown if cholecystitis is also more common during this time.
Genetics • Although cholecystitis tends to be more severe in men, gallstones are more than twice as common in women than in men.
The incidence of acalculous cholecystitis is somewhat higher in men.
OVERALL PREVENTION
Gallstone development can be avoided with a low-fat diet. Acute cholecystitis has also become less common when biliary colic is treated with stone removal or cholecystectomy.
PATHOPHYSIOLOGY Gallstone blockage is the cause of acute calculous cholecystitis.
Gallbladder stasis and stagnated bile cause acalculous cholecystitis.
• Common bile duct blockage causes acute cholangitis, which is accompanied by elevated biliary
pressures. Cholangitis symptoms may arise from the movement of bacteria or endotoxins from the bile ducts into the circulation and lymphatic systems due to obstruction.
ETIOLOGY • Progesterone, fibrate, estrogen, ceftriaxone, and octreotide are among the drugs that have been linked to the development of cholestasis or gallstone formation that results in acute cholecystitis. Additional medications linked to cholecystitis include dapsone, which promotes hemolysis, erythromycin and ampicillin hypersensitivity, and opioids and anticholinergic drugs, which impair gallbladder motility.
• Polymicrobial illnesses predominate. Escherichia coli, Klebsiella species, Enterococcus species, Enterobacter species, and Pseudomonas species are the most frequently cultured organisms. Following surgery or an interventional endoscopy, Staphylococcus and Pseudomonas may be discovered. Patients with diabetes, the elderly, and those recovering from biliary system surgeries are more likely to have anaerobes.
• Choledocholithiasis, malignant biliary strictures, iatrogenic bile duct damage, and stricture of the bile duct are obstructive lesions that increase the risk of pyogenic bacterial cholangitis.
primary sclerosing cholangitis, congenital intrahepatic biliary dilatation (Caroli's disease), biliary anastomosis, and parasite entrance into the bile duct. The trematodes Clonorchis and Opisthorchis, the nematodes Ascaris and, infrequently, Strongyloides, and the cestodes Echinococcus granulosus and Echinococcus multilocularis are among the parasites linked to cholangitis.
History of Diagnosis
• Abdominal pain in the right upper quadrant that may radiate to the infrascapular region is a common symptom of biliary tract disease.
• Acute cholecystitis frequently starts with a fever and biliary colic attack that gets worse over time.
– A history of previous assaults that ended on their own is reported by 60–70% of patients.
– Cholecystitis (and cholangitis) causes constant pain, in contrast to biliary colic.
• Undefined stomach pain or an inexplicable fever are two symptoms of acalculous cholecystitis. Particularly in critically ill patients who are not responding, a high index of suspicion is necessary.
• The symptoms of acute cholangitis frequently include fever and chills, jaundice, and discomfort in the right upper quadrant (Charcot's triad).
– Charcot's triad is only present in 50–70% of patients. Lethargy, mental disorientation, and shock (Reynolds' pentad) are further presenting symptoms.
– Disseminated intravascular coagulation and renal failure are other indicators of organ failure.
Physical examination: Tenderness in the right upper quadrant of the abdomen is 98% sensitive to biliary tract illness. The palpation of a mass in the right upper quadrant is one of the other less sensitive findings. Abdominal discomfort in the right upper quadrant is one of the findings that point to biliary tract disease.
• Acute cholecystitis can be detected by the presence of a Murphy's sign, which is pain felt when the right subcostal region is palpated during inspiration.
Tests for Diagnosis and Interpretation Lab
• Fever and leukocytosis are common symptoms in patients with acute cholecystitis.
WBC count >12,500 cells/mm3 or temperature >38.5°C indicate the presence of infection.
The severity of the condition is indicated by anomalies in the BUN, Cr, platelet count, and prothrombin time.
• Half of patients had slightly raised serum bilirubin, and 25% have slightly elevated serum aminotransferases.
• There is frequently an increase in C-reactive protein.
• Concomitant gallstone pancreatitis or gangrenous cholecystitis may be indicated by elevated amylase values.
• 90% of patients with choledocholithiasis and jaundice have positive biliary cultures, while 50% of patients with biliary blockage do. Incomplete bile duct obstruction is more likely to result in positive cultures than full obstruction. Although bacterial colonization is typically linked to advanced age (>70 years), prior biliary system operations, and common duct stones, bile in healthy persons is typically sterile.
Imagining
• The diagnosis of cholecystitis is often established by ultrasound.
– Gallbladder wall thickening greater than 2 mm, pericholecystic fluid, intramural gas, ductal dilatation, or direct discomfort when the probe is put over the gallbladder (sonographic Murphy's sign) are all signs of acute cholecystitis.
– A sonographic Murphy's sign and the presence of stones have a 92% positive predictive value (PPV).
– The gallbladder wall thickening and stone presence had a 95% PPV.
– When there are no stones and a normal gallbladder wall or Murphy's sign is missing, the negative predictive value is 95%.
Diagnostic Techniques and Other
• Hepatobiliary scintigraphy uses an intravenous injection of technetium-labeled iminodiacetic acid analogs to monitor the flow of bile. It is 80–90% sensitive for acute cholecystitis and shows occlusion of the cystic duct if there is no gallbladder filling 60 minutes after treatment. Usually utilized when ultrasonography is not diagnostic, the false positive rate ranges from 10% to 20%.
• When used in conjunction with US to diagnose cholangitis, CT with intravenous contrast may show pneumobilia and bile duct dilatation.
TREATMENT MEDICATION
Patients with acute cholecystitis or cholangitis should receive antibiotics that target Enterobacteriaceae.
For mild-to-moderate instances of community-acquired acute cholecystitis, the Infectious Diseases Society of America advises using cefazolin, cefuroxime, or ceftriaxone.
• Vancomycin should be added to healthcare-associated biliary infections of any severity. • Broad-spectrum antibiotic therapy, such as imipenem-cilastatin, meropenem, piperacillin-tazobactam, ciprofloxacin, levofloxacin, or cefepime, is advised for acute cholangitis or acute cholecystitis in the presence of advanced age, immunocompromised patients, or severe physiologic disturbance.
Give antibiotics as a preventative measure for cholecystectomy or to patients who have diabetes, immunodeficiency, or advanced age.
• Start taking antibiotics an hour before and stop taking them
• antibiotics for acute cholecystitis without signs of infection outside the gallbladder within 24 hours of cholecystectomy.
Since the pathogenicity of enterococci in immunocompetent hosts has not been established, anti-enterococcal medication is not necessary for community-acquired biliary infections in these individuals.
• In the event that post-operative difficulties develop, intra-operative gallbladder bile cultures may be utilized to inform antibiotic selection.
• Systemic antibiotics and, in cases of more severe illness, biliary drainage are used to treat acute cholangitis.
ADDITIONAL MEDICATION
Overall Actions
• Correct fluid status and electrolyte imbalances with intravenous fluids; • Stop oral intake and start nasogastric suction.
• The most common analgesics are meperidine or pentazocine.
OTHER PROCEDURES AND SURGERY
• Because to the lower rate of complications, fewer expenses, and shorter recovery times, early cholecystectomy is preferable over delayed (post-"cooling off") cholecystectomy.
• Biliary decompression can be achieved via endoscopic gallbladder draining and stenting or percutaneous transhepatic gallbladder aspiration, in addition to open or laparoscopic cholecystectomy.
• When a gallbladder perforation or emphysematous cholecystitis, two complications of acute cholecystitis, are suspected or confirmed, an urgent cholecystectomy is necessary.
• In cases of acute cholangitis, biliary drainage can be carried out percutaneously or via endoscopy (ERCP). It might be necessary to use emergency surgical drainage.
PROGNOSIS FOR ONGOING CARE • Of the 75% of patients with acute cholecystitis whose symptoms resolve, around a quarter will relapse within a year, and 60% will have at least one recurrent episode within six years.
• Acute cholangitis has a mortality rate of 10–30%.
DIFFICULTIES
• Chronic cholecystitis can be brought on by recurrent episodes of mild acute cholecystitis or by long-term irritation from big gallstones.
• Acalculous cholecystitis has a higher rate of complications than calculous cholecystitis.
• Gallbladder empyema carries a substantial risk of perforation and/or Gram-negative sepsis.
• Inflammation and adhesion development may cause fistulization into a nearby organ that is adherent to the gallbladder wall.
• Elderly people are far more likely than younger patients to experience severe acute cholangitis (along by shock or mental impairment).
• Sepsis and hepatic abscess are possible outcomes of acute cholangitis.
• Cholangitis may be obscured by an enlarged and painful liver caused by the abscess.
DESCRIPTION: Cholangitis is a clinical diagnosis based on symptoms and indicators of systemic sepsis that originate in the biliary tract, while cholecystitis is an acute or chronic inflammation of the gallbladder.
• Gallbladder inflammation, also known as gaseous cholecystitis, is typified by gas in the gallbladder lumen that may penetrate the gallbladder wall and/or surrounding tissues.
EPIDEMIOLOGY • Three to ten percent of patients with stomach pain have acute cholecystitis. In patients older than 50, the frequency rises to 20%.
• Biliary colic affects 1–4% of cholelithiasis patients each year. Twenty percent of people with symptoms go on to develop acute cholecystitis if they are not treated.
RISK ELEMENTS
• Cholelithiasis is the cause of 90–95% of acute cholecystitis cases.
• The risk of cholelithiasis and cholecystitis is elevated by both obesity and severe dieting.
• Hemolytic disorders, such as sickle cell disease and G6PD deficiency, raise the incidence of pigment stones and the biliary blockage that follows.
• Some ethnic groups, like Pima Indians, are more likely to experience stone formation.
Diabetes mellitus, ischemia, sepsis, and other low-flow states; motility disorders; severe burns or trauma; direct chemical injury; allergic reactions; prolonged use of total parenteral nutrition; vasculitis; collagen disease; sarcoidosis; infections (such as TB, actinomycosis, ascariasis, and HIV/AIDS); and gallbladder torsion are all linked to acalculous cholecystitis.
– In AIDS patients, acalculous cholecystitis usually develops earlier in life and is linked to infections with the cytomegalovirus (CMV) and cryptosporidium.
• Patients with diabetes mellitus and the elderly are more likely to develop emphysematous cholecystitis.
• An infectious consequence of retrograde endoscopic cholangiopancreatography (ERCP).
Considerations for Pregnancy
Although cholelithiasis is common during pregnancy, it is unknown if cholecystitis is also more common during this time.
Genetics • Although cholecystitis tends to be more severe in men, gallstones are more than twice as common in women than in men.
The incidence of acalculous cholecystitis is somewhat higher in men.
OVERALL PREVENTION
Gallstone development can be avoided with a low-fat diet. Acute cholecystitis has also become less common when biliary colic is treated with stone removal or cholecystectomy.
PATHOPHYSIOLOGY Gallstone blockage is the cause of acute calculous cholecystitis.
Gallbladder stasis and stagnated bile cause acalculous cholecystitis.
• Common bile duct blockage causes acute cholangitis, which is accompanied by elevated biliary
pressures. Cholangitis symptoms may arise from the movement of bacteria or endotoxins from the bile ducts into the circulation and lymphatic systems due to obstruction.
ETIOLOGY • Progesterone, fibrate, estrogen, ceftriaxone, and octreotide are among the drugs that have been linked to the development of cholestasis or gallstone formation that results in acute cholecystitis. Additional medications linked to cholecystitis include dapsone, which promotes hemolysis, erythromycin and ampicillin hypersensitivity, and opioids and anticholinergic drugs, which impair gallbladder motility.
• Polymicrobial illnesses predominate. Escherichia coli, Klebsiella species, Enterococcus species, Enterobacter species, and Pseudomonas species are the most frequently cultured organisms. Following surgery or an interventional endoscopy, Staphylococcus and Pseudomonas may be discovered. Patients with diabetes, the elderly, and those recovering from biliary system surgeries are more likely to have anaerobes.
• Choledocholithiasis, malignant biliary strictures, iatrogenic bile duct damage, and stricture of the bile duct are obstructive lesions that increase the risk of pyogenic bacterial cholangitis.
primary sclerosing cholangitis, congenital intrahepatic biliary dilatation (Caroli's disease), biliary anastomosis, and parasite entrance into the bile duct. The trematodes Clonorchis and Opisthorchis, the nematodes Ascaris and, infrequently, Strongyloides, and the cestodes Echinococcus granulosus and Echinococcus multilocularis are among the parasites linked to cholangitis.
History of Diagnosis
• Abdominal pain in the right upper quadrant that may radiate to the infrascapular region is a common symptom of biliary tract disease.
• Acute cholecystitis frequently starts with a fever and biliary colic attack that gets worse over time.
– A history of previous assaults that ended on their own is reported by 60–70% of patients.
– Cholecystitis (and cholangitis) causes constant pain, in contrast to biliary colic.
• Undefined stomach pain or an inexplicable fever are two symptoms of acalculous cholecystitis. Particularly in critically ill patients who are not responding, a high index of suspicion is necessary.
• The symptoms of acute cholangitis frequently include fever and chills, jaundice, and discomfort in the right upper quadrant (Charcot's triad).
– Charcot's triad is only present in 50–70% of patients. Lethargy, mental disorientation, and shock (Reynolds' pentad) are further presenting symptoms.
– Disseminated intravascular coagulation and renal failure are other indicators of organ failure.
Physical examination: Tenderness in the right upper quadrant of the abdomen is 98% sensitive to biliary tract illness. The palpation of a mass in the right upper quadrant is one of the other less sensitive findings. Abdominal discomfort in the right upper quadrant is one of the findings that point to biliary tract disease.
• Acute cholecystitis can be detected by the presence of a Murphy's sign, which is pain felt when the right subcostal region is palpated during inspiration.
Tests for Diagnosis and Interpretation Lab
• Fever and leukocytosis are common symptoms in patients with acute cholecystitis.
WBC count >12,500 cells/mm3 or temperature >38.5°C indicate the presence of infection.
The severity of the condition is indicated by anomalies in the BUN, Cr, platelet count, and prothrombin time.
• Half of patients had slightly raised serum bilirubin, and 25% have slightly elevated serum aminotransferases.
• There is frequently an increase in C-reactive protein.
• Concomitant gallstone pancreatitis or gangrenous cholecystitis may be indicated by elevated amylase values.
• 90% of patients with choledocholithiasis and jaundice have positive biliary cultures, while 50% of patients with biliary blockage do. Incomplete bile duct obstruction is more likely to result in positive cultures than full obstruction. Although bacterial colonization is typically linked to advanced age (>70 years), prior biliary system operations, and common duct stones, bile in healthy persons is typically sterile.
Imagining
• The diagnosis of cholecystitis is often established by ultrasound.
– Gallbladder wall thickening greater than 2 mm, pericholecystic fluid, intramural gas, ductal dilatation, or direct discomfort when the probe is put over the gallbladder (sonographic Murphy's sign) are all signs of acute cholecystitis.
– A sonographic Murphy's sign and the presence of stones have a 92% positive predictive value (PPV).
– The gallbladder wall thickening and stone presence had a 95% PPV.
– When there are no stones and a normal gallbladder wall or Murphy's sign is missing, the negative predictive value is 95%.
Diagnostic Techniques and Other
• Hepatobiliary scintigraphy uses an intravenous injection of technetium-labeled iminodiacetic acid analogs to monitor the flow of bile. It is 80–90% sensitive for acute cholecystitis and shows occlusion of the cystic duct if there is no gallbladder filling 60 minutes after treatment. Usually utilized when ultrasonography is not diagnostic, the false positive rate ranges from 10% to 20%.
• When used in conjunction with US to diagnose cholangitis, CT with intravenous contrast may show pneumobilia and bile duct dilatation.
TREATMENT MEDICATION
Patients with acute cholecystitis or cholangitis should receive antibiotics that target Enterobacteriaceae.
For mild-to-moderate instances of community-acquired acute cholecystitis, the Infectious Diseases Society of America advises using cefazolin, cefuroxime, or ceftriaxone.
• Vancomycin should be added to healthcare-associated biliary infections of any severity. • Broad-spectrum antibiotic therapy, such as imipenem-cilastatin, meropenem, piperacillin-tazobactam, ciprofloxacin, levofloxacin, or cefepime, is advised for acute cholangitis or acute cholecystitis in the presence of advanced age, immunocompromised patients, or severe physiologic disturbance.
Give antibiotics as a preventative measure for cholecystectomy or to patients who have diabetes, immunodeficiency, or advanced age.
• Start taking antibiotics an hour before and stop taking them
• antibiotics for acute cholecystitis without signs of infection outside the gallbladder within 24 hours of cholecystectomy.
Since the pathogenicity of enterococci in immunocompetent hosts has not been established, anti-enterococcal medication is not necessary for community-acquired biliary infections in these individuals.
• In the event that post-operative difficulties develop, intra-operative gallbladder bile cultures may be utilized to inform antibiotic selection.
• Systemic antibiotics and, in cases of more severe illness, biliary drainage are used to treat acute cholangitis.
ADDITIONAL MEDICATION
Overall Actions
• Correct fluid status and electrolyte imbalances with intravenous fluids; • Stop oral intake and start nasogastric suction.
• The most common analgesics are meperidine or pentazocine.
OTHER PROCEDURES AND SURGERY
• Because to the lower rate of complications, fewer expenses, and shorter recovery times, early cholecystectomy is preferable over delayed (post-"cooling off") cholecystectomy.
• Biliary decompression can be achieved via endoscopic gallbladder draining and stenting or percutaneous transhepatic gallbladder aspiration, in addition to open or laparoscopic cholecystectomy.
• When a gallbladder perforation or emphysematous cholecystitis, two complications of acute cholecystitis, are suspected or confirmed, an urgent cholecystectomy is necessary.
• In cases of acute cholangitis, biliary drainage can be carried out percutaneously or via endoscopy (ERCP). It might be necessary to use emergency surgical drainage.
PROGNOSIS FOR ONGOING CARE • Of the 75% of patients with acute cholecystitis whose symptoms resolve, around a quarter will relapse within a year, and 60% will have at least one recurrent episode within six years.
• Acute cholangitis has a mortality rate of 10–30%.
DIFFICULTIES
• Chronic cholecystitis can be brought on by recurrent episodes of mild acute cholecystitis or by long-term irritation from big gallstones.
• Acalculous cholecystitis has a higher rate of complications than calculous cholecystitis.
• Gallbladder empyema carries a substantial risk of perforation and/or Gram-negative sepsis.
• Inflammation and adhesion development may cause fistulization into a nearby organ that is adherent to the gallbladder wall.
• Elderly people are far more likely than younger patients to experience severe acute cholangitis (along by shock or mental impairment).
• Sepsis and hepatic abscess are possible outcomes of acute cholangitis.
• Cholangitis may be obscured by an enlarged and painful liver caused by the abscess.
